3124 lines
310 KiB
Text
3124 lines
310 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK578166">
|
|
<meta name="ncbi_domain" content="niceng95er5">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK578166/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence review for the management of non-specific symptoms related to Lyme disease - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence review for the management of non-specific symptoms related to Lyme disease - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_title" content="Evidence review for the management of non-specific symptoms related to Lyme disease">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2018/04">
|
|
<meta name="citation_author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_pmid" content="35201694">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK578166/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence review for the management of non-specific symptoms related to Lyme disease">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Contributor" content="National Guideline Centre (UK)">
|
|
<meta name="DC.Date" content="2018/04">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK578166/">
|
|
<meta name="og:title" content="Evidence review for the management of non-specific symptoms related to Lyme disease">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK578166/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng95er5-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng95er5/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK578166/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8BEB4E7D75FBB1000000000092007F.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK578166/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK578166/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK578166/&text=Evidence%20review%20for%20the%20management%20of%20non-specific%20symptoms%20related%20to%20Lyme%20disease"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK578166/?report=classic">Switch to classic view</a><a href="/books/n/niceng95er5/pdf/">PDF (409K)</a><a href="/books/n/niceng95er5/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK578166%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8BEB4E7D75FBB1000000000092007F.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng95er5-lrg.png" alt="Cover of Evidence review for the management of non-specific symptoms related to Lyme disease" /></a></div><div class="bkr_bib"><h1 id="_NBK578166_"><span itemprop="name">Evidence review for the management of non-specific symptoms related to
|
|
Lyme disease</span></h1><div class="subtitle">Lyme disease: diagnosis and management</div><p><b>Evidence review E</b></p><p><i>NICE Guideline, No. 95</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">National Guideline Centre (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2018 Apr</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-2919-1</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2018.</div></div><div class="bkr_clear"></div></div><div id="ch5.s1"><h2 id="_ch5_s1_">1. Management (non-specific symptoms)</h2><div id="ch5.s1.1"><h3>1.1. Review question: What is the most clinically and cost-effective
|
|
treatment for people who have non-specific symptoms that may be related
|
|
to Lyme disease?</h3></div><div id="ch5.s1.2"><h3>1.2. Introduction</h3><p>People with Lyme disease may present with non-specific or non-focal
|
|
symptoms such as headache, fatigue, dizziness and muscle pain, which can
|
|
be distressing and impact their quality of life. This review question is
|
|
important to understand the most appropriate antibiotic and duration of
|
|
treatment for these presentations.</p><p>These people might not have the typical erythema migrans (EM) rash at the
|
|
site of the tick bite and there is currently no standardised management
|
|
approach for these people.</p><p>For full details, see the review protocol in <a href="#ch5.appa">appendix A</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch5tab1"><a href="/books/NBK578166/table/ch5.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figch5tab1" rid-ob="figobch5tab1"><img class="small-thumb" src="/books/NBK578166/table/ch5.tab1/?report=thumb" src-large="/books/NBK578166/table/ch5.tab1/?report=previmg" alt="Table 1. PICO characteristics of review question." /></a><div class="icnblk_cntnt"><h4 id="ch5.tab1"><a href="/books/NBK578166/table/ch5.tab1/?report=objectonly" target="object" rid-ob="figobch5tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div></div><div id="ch5.s1.3"><h3>1.3. Clinical evidence</h3><div id="ch5.s1.3.1"><h4>1.3.1. Included studies</h4><p>No relevant RCTs and cohort studies assessing the effectiveness of
|
|
antimicrobial therapy in people with solely non-specific symptoms
|
|
and no prior antibiotic treatment of Lyme disease were
|
|
identified.</p><p>Studies in people with Lyme disease, who had persistent, non-specific
|
|
symptoms despite having undergone antibiotic treatment, were
|
|
included in the chapter on the management of persistent symptoms
|
|
related to Lyme disease.</p><p>See also the study selection flow chart in <a href="#ch5.appc">appendix C</a>.</p></div><div id="ch5.s1.3.2"><h4>1.3.2. Excluded studies</h4><p>See the excluded studies list in <a href="#ch5.appi">appendix I</a>.</p></div><div id="ch5.s1.3.3"><h4>1.3.3. Summary of clinical studies included in the evidence
|
|
review</h4><p>No evidence was identified.</p></div><div id="ch5.s1.3.4"><h4>1.3.4. Quality assessment of clinical studies included in the evidence
|
|
review</h4><p>No evidence was identified.</p></div></div><div id="ch5.s1.4"><h3>1.4. Economic evidence</h3><div id="ch5.s1.4.1"><h4>1.4.1. Included studies</h4><p>No relevant health economic studies were identified.</p></div><div id="ch5.s1.4.2"><h4>1.4.2. Excluded studies</h4><p>No relevant health economic studies were identified and excluded.</p><p>See also the health economic study selection flow chart in <a href="#ch5.appg">appendix G</a>.</p></div><div id="ch5.s1.4.3"><h4>1.4.3. Unit costs</h4><p>The following unit costs were presented to the committee to aid
|
|
consideration of cost-effectiveness.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch5tab2"><a href="/books/NBK578166/table/ch5.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figch5tab2" rid-ob="figobch5tab2"><img class="small-thumb" src="/books/NBK578166/table/ch5.tab2/?report=thumb" src-large="/books/NBK578166/table/ch5.tab2/?report=previmg" alt="Table 2. UK costs of antimicrobials." /></a><div class="icnblk_cntnt"><h4 id="ch5.tab2"><a href="/books/NBK578166/table/ch5.tab2/?report=objectonly" target="object" rid-ob="figobch5tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">UK costs of antimicrobials. </p></div></div><p>The cost of intravenous antibiotics will vary depending on where
|
|
these are administered and by whom. These costs will include some of
|
|
the following cost components: <ul id="ch5.l14"><li id="ch5.lt47" class="half_rhythm"><div>antibiotic</div></li><li id="ch5.lt48" class="half_rhythm"><div>nursing time (for example, Band 6 nurse, £44 per
|
|
hour, PSSRU 2016<a class="bibr" href="#ch5.ref40" rid="ch5.ref40"><sup>40</sup></a>)</div></li><li id="ch5.lt49" class="half_rhythm"><div>clinic space and clerical time (for outpatient
|
|
administration)</div></li><li id="ch5.lt50" class="half_rhythm"><div>travel time (for home administration)</div></li><li id="ch5.lt51" class="half_rhythm"><div>hospital bed (for inpatient administration)</div></li><li id="ch5.lt52" class="half_rhythm"><div>consumables (for example, cannula, needles, syringes,
|
|
dressing, IV giving set and glucose or sodium chloride
|
|
solution).</div></li></ul></p><p>A large proportion of the total cost of intravenous antibiotics is
|
|
likely to be the cost of administration rather than the drug itself.
|
|
As a result, intravenous drugs that have multiple doses administered
|
|
per day will be more costly than those administered once daily. This
|
|
was explored in a detailed costing analysis conducted for the NICE
|
|
CG102 (Meningitis [bacterial] and meningococcal septicaemia in under
|
|
16s).<a class="bibr" href="#ch5.ref114" rid="ch5.ref114"><sup>114</sup></a> In this analysis, they found that
|
|
ceftriaxone was the cheapest antibiotic when compared to cefotaxime
|
|
and benzylpenicillin. This was due to savings in staff time
|
|
associated with once daily dosing, which offset the higher cost of
|
|
the drug itself.</p><div id="ch5.s1.4.3.1"><h5>Inpatient administration</h5><p>Intravenous antibiotics administered in an inpatient setting will
|
|
incur the cost of an inpatient stay, which is assumed to include
|
|
intravenous antibiotics treatment as part of the unit cost. The
|
|
estimated weighted average unit cost of non-elective inpatient
|
|
stays and day cases for infectious disease in adults and
|
|
children are summarised in the table below using the NHS
|
|
reference costs 2015/2016.<a class="bibr" href="#ch5.ref45" rid="ch5.ref45"><sup>45</sup></a></p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch5tab3"><a href="/books/NBK578166/table/ch5.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figch5tab3" rid-ob="figobch5tab3"><img class="small-thumb" src="/books/NBK578166/table/ch5.tab3/?report=thumb" src-large="/books/NBK578166/table/ch5.tab3/?report=previmg" alt="Table 3. Unit costs of inpatient administration." /></a><div class="icnblk_cntnt"><h4 id="ch5.tab3"><a href="/books/NBK578166/table/ch5.tab3/?report=objectonly" target="object" rid-ob="figobch5tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Unit costs of inpatient administration. </p></div></div></div><div id="ch5.s1.4.3.2"><h5>Outpatient administration</h5><p>Intravenous antibiotics may also be administered as part of an
|
|
outpatient parenteral antibiotic therapy (OPAT) service, which
|
|
is available in some hospitals. This allows for administration
|
|
in an outpatient clinic or in a home setting by a district nurse
|
|
and is for people who require parenteral treatment but are
|
|
otherwise stable and well enough not to be in hospital. There is
|
|
currently no NHS reference cost for this service.</p><p>A UK study by Chapman 2009<a class="bibr" href="#ch5.ref29" rid="ch5.ref29"><sup>29</sup></a> reports that this type of service
|
|
costs between 41% and 61% of the equivalent inpatient costs.
|
|
Based on these estimates from Chapman 2009 and the unit cost for
|
|
an adult day case in <a class="figpopup" href="/books/NBK578166/table/ch5.tab3/?report=objectonly" target="object" rid-figpopup="figch5tab3" rid-ob="figobch5tab3">Table
|
|
3</a>, the cost of OPAT would be approximately
|
|
£144 to £215 per day. These costs would include
|
|
the cost of the drug as well as the administration.</p></div></div></div><div id="ch5.s1.5"><h3>1.5. Resource impact</h3><p>We do not expect recommendations resulting from this review area to have
|
|
a significant impact on resources.</p></div><div id="ch5.s1.6"><h3>1.6. Evidence statements</h3><div id="ch5.s1.6.1"><h4>1.6.1. Clinical evidence statements</h4><p>No relevant published evidence was identified.</p></div><div id="ch5.s1.6.2"><h4>1.6.2. Health economic evidence statements</h4><p>No relevant economic evaluations were identified.</p></div></div><div id="ch5.s1.7"><h3>1.7. The committee’s discussion of the evidence</h3><div id="ch5.s1.7.1"><h4>1.7.1. Interpreting the evidence</h4><div id="ch5.s1.7.1.1"><h5>1.7.1.1. The outcomes that matter most</h5><p>The guideline committee considered quality of life, cure or the
|
|
resolution of non-specific Lyme disease symptoms, the reduction
|
|
of non-specific Lyme disease symptoms, and the relapse of
|
|
non-specific Lyme disease symptoms to be critical outcomes.
|
|
Adverse events as a result of treatment were considered to be an
|
|
important outcome.</p><p>No evidence on non-specific symptoms associated with Lyme disease
|
|
was identified.</p></div><div id="ch5.s1.7.1.2"><h5>1.7.1.2. The quality of the evidence</h5><p>No evidence on non-specific symptoms associated with Lyme disease
|
|
was identified in this review.</p></div><div id="ch5.s1.7.1.3"><h5>1.7.1.3. Benefits and harms</h5><p>No evidence on non-specific symptoms associated with Lyme disease
|
|
was identified in this review.</p></div></div><div id="ch5.s1.7.2"><h4>1.7.2. Cost effectiveness and resource use</h4><p>No health economic evidence was identified. The unit costs of
|
|
different oral and intravenous antimicrobials were presented to the
|
|
committee. The cost of oral doxycycline and amoxicillin is much
|
|
lower than that of intravenous ceftriaxone (£4.57 and
|
|
£7.62 versus £21.63 in adults). The committee also
|
|
considered the cost of intravenous administration, which would
|
|
include the cost of nurse time, clinic space and clerical time (if
|
|
administered in an outpatient setting), nurse travel time (if
|
|
administered at home) and disposables required for administration.
|
|
These costs would likely be greater than the cost of the antibiotics
|
|
themselves.</p><p>The committee recommended oral doxycycline or amoxicillin for people
|
|
with non-specific Lyme disease. The dose and duration is based on
|
|
committee consideration of evidence for other presentations of Lyme
|
|
disease and consensus. For those in whom both doxycycline and
|
|
amoxicillin are contraindicated, azithromycin is recommended. The
|
|
unit cost of azithromycin is low at £3.75 for 500 mg, once
|
|
daily for 3 days for 3 weeks.</p><p>The recommendations for children closely reflect those for adults,
|
|
unless drugs are contraindicated. For younger children, oral
|
|
suspension formulations may be required rather than tablets. The
|
|
unit costs of the recommended antimicrobials for children are not
|
|
dissimilar to those for adults.</p><p>The committee considered the different adverse event profiles of
|
|
different antimicrobials and whether these may impact the costs of
|
|
managing Lyme disease as well as their impact on the
|
|
patient’s quality of life. Doxycycline adverse events, for
|
|
example, include photosensitivity, nausea and vomiting. It was also
|
|
noted that a rare side effect of azithromycin is QT prolongation. In
|
|
practice, if a patient experiences any of these adverse events,
|
|
these would be managed by switching to another antimicrobial;
|
|
therefore, the cost to the NHS would be a consultation with a GP and
|
|
additional antimicrobials. These costs are considered to be low and
|
|
would be offset by the cure and reduction of symptoms after
|
|
successful treatment of Lyme disease.</p><p>The committee agreed that this potential change in practice in terms
|
|
of a longer course of antimicrobials would not result in a
|
|
significant resource impact given the relatively small number of
|
|
people diagnosed with Lyme disease.</p></div><div id="ch5.s1.7.3"><h4>1.7.3. Other factors the committee took into account</h4><p>Non-specific symptoms could be an indication of an acute infection
|
|
without the involvement of specific organ systems. The committee
|
|
agreed that people with a positive test result for Lyme disease and
|
|
non-specific symptoms should be treated in the same way as people
|
|
with an erythema migrans rash.</p><p>The evidence identified through the evidence review on the management
|
|
of erythema migrans influenced the recommendations made for the
|
|
management of non-specific symptoms. There was evidence that
|
|
doxycycline was more effective than some other antibiotics, but
|
|
there was no clear evidence that doxycycline was more effective than
|
|
an amoxicillin/probenecid combination or azithromycin. The committee
|
|
noted that doxycycline and amoxicillin can penetrate the
|
|
blood-cerebrospinal fluid barrier and pass into the central nervous
|
|
system, whereas azithromycin cannot. Doxycycline can also be taken
|
|
as a single daily dose.</p><p>Therefore, the committee recommended doxycycline as the antibiotic of
|
|
choice. In cases where doxycycline is contraindication, amoxicillin
|
|
should be offered to the patient. Azithromycin can be offered if
|
|
doxycycline and amoxicillin are contraindicated. The guideline
|
|
recommends that care of children and young people less than 18 years
|
|
should be discussed with a specialist for advice about diagnosis and
|
|
management. In children under the age of 12, amoxicillin is
|
|
recommended as the antibiotic of choice.</p><p>The guideline committee was aware that specialists do offer
|
|
doxycycline in children aged 9 years and above as a result of
|
|
indirect evidence from the United States and Scandinavia despite no
|
|
licence or BNFC dose., There is also increasing indirect evidence
|
|
from use in other conditions in the United States and Canada that
|
|
doxycycline does not cause teeth staining when used for short course
|
|
(less than 4 weeks) in children aged 2 years and older and
|
|
international practice is moving to recommend use above 2 years. UK
|
|
specialist clinicians may choose to use doxycycline as second line
|
|
where a CSF-penetrating oral antibiotic is required, although the
|
|
lack of direct evidence, lack of licence and lack of BNFC dose
|
|
regimen has so far limited UK use in children aged 8 and under.
|
|
Where used, in the United States and Canada, 1 dose regimen of
|
|
doxycycline for children under 45 kilograms is: 5 milligram/kilogram
|
|
in 2 divided doses on day 1 followed by 2.5 milligram/kilogram daily
|
|
in 1 or 2 divided doses with a maximum for severe infections, up to
|
|
5 milligram/kilogram daily.</p><p>Azithromycin should be otherwise be offered in cases where
|
|
amoxicillin is contraindicated. The committee made research
|
|
recommendations for the development of a core outcome set for use in
|
|
studies of Lyme disease and a research recommendation for antibiotic
|
|
management. These are outlines in detail in <a href="/books/n/niceng95er4/?report=reader" class="toc-item">appendix J</a> of <a href="/books/n/niceng95er4/?report=reader" class="toc-item">evidence report D</a>.</p></div></div></div><div id="ch5.rl.r1"><h2 id="_ch5_rl_r1_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="ch5.ref1">Aberer
|
|
E,
|
|
Kahofer
|
|
P,
|
|
Binder
|
|
B,
|
|
Kinaciyan
|
|
T,
|
|
Schauperl
|
|
H,
|
|
Berghold
|
|
A.
|
|
Comparison of a two- or three-week regimen and a
|
|
review of treatment of erythema migrans with
|
|
phenoxymethylpenicillin.
|
|
Dermatology. 2006;
|
|
212(2):160–167 [<a href="https://pubmed.ncbi.nlm.nih.gov/16484823" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16484823</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="ch5.ref2">Abrutyn
|
|
E. New uses
|
|
for old drugs. Infectious Disease Clinics of
|
|
North America. 1989;
|
|
3(3):653–664 [<a href="https://pubmed.ncbi.nlm.nih.gov/2527907" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2527907</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="ch5.ref3">Agger
|
|
WA,
|
|
Callister
|
|
SM,
|
|
Jobe
|
|
DA. In vitro
|
|
susceptibilities of Borrelia burgdorferi to five oral cephalosporins
|
|
and ceftriaxone. Antimicrobial Agents and
|
|
Chemotherapy. 1992;
|
|
36(8):1788–1790 [<a href="/pmc/articles/PMC192050/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC192050</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1416868" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1416868</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="ch5.ref4">Agus
|
|
B. The
|
|
recognition and treatment of Lyme disease.
|
|
Primary Care Update for Ob/Gyns. 1995;
|
|
2(6):200–203</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="ch5.ref5">Agwuh
|
|
KN,
|
|
MacGowan
|
|
A.
|
|
Pharmacokinetics and pharmacodynamics of the
|
|
tetracyclines including glycylcyclines.
|
|
Journal of Antimicrobial Chemotherapy.
|
|
2006;
|
|
58(2):256–265 [<a href="https://pubmed.ncbi.nlm.nih.gov/16816396" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16816396</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="ch5.ref6">Ahmed
|
|
A. When is
|
|
facial paralysis Bell palsy? current diagnosis and
|
|
treatment. Cleveland Clinic Journal of
|
|
Medicine. 2005;
|
|
72(5):398–405 [<a href="https://pubmed.ncbi.nlm.nih.gov/15929453" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15929453</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="ch5.ref7">Ahmed
|
|
S,
|
|
Rashid
|
|
S,
|
|
Chaudhary
|
|
A,
|
|
Bischof
|
|
E. A patient
|
|
with Lyme disease: complete heart block treated with
|
|
antibiotics. Primary Care Cardiovascular
|
|
Journal. 2013;
|
|
6(3):117–118</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="ch5.ref8">Alarcon
|
|
GS,
|
|
Mikhail
|
|
IS.
|
|
Antimicrobials in the treatment of rheumatoid
|
|
arthritis and other arthritides: a clinical
|
|
perspective. American Journal of the Medical
|
|
Sciences. 1994;
|
|
308(3):201–209 [<a href="https://pubmed.ncbi.nlm.nih.gov/8074141" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8074141</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="ch5.ref9">Andiman
|
|
WA. Lyme
|
|
disease: epidemiology, etiology, clinical spectrum, diagnosis, and
|
|
treatment. Advances in Pediatric Infectious
|
|
Diseases. 1986;
|
|
1:163–186 [<a href="https://pubmed.ncbi.nlm.nih.gov/3331275" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3331275</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="ch5.ref10">Anonymous.
|
|
Antibiotic prophylaxis of Lyme disease following
|
|
recognized tick bite. Bacterial Zoonoses Branch, Division of
|
|
Vector-Borne Infectious Diseases National Center for Infectious
|
|
Diseases, Centers for Disease Control.
|
|
Connecticut Medicine. 1991;
|
|
55(12):691–693 [<a href="https://pubmed.ncbi.nlm.nih.gov/1790707" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1790707</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="ch5.ref11">Arvikar
|
|
SL,
|
|
Steere
|
|
AC.
|
|
Diagnosis and treatment of Lyme
|
|
arthritis. Infectious Disease Clinics of
|
|
North America. 2015;
|
|
29(2):269–280 [<a href="/pmc/articles/PMC4443866/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4443866</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25999223" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25999223</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="ch5.ref12">Auwaerter
|
|
PG,
|
|
Aucott
|
|
J,
|
|
Dumler
|
|
JS. Lyme
|
|
borreliosis (Lyme disease): molecular and cellular pathobiology and
|
|
prospects for prevention, diagnosis and treatment.
|
|
Expert Reviews in Molecular Medicine.
|
|
2004;
|
|
6(2):1–22 [<a href="https://pubmed.ncbi.nlm.nih.gov/14987414" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14987414</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="ch5.ref13">Bennet
|
|
L,
|
|
Danell
|
|
S,
|
|
Berglund
|
|
J. Clinical
|
|
outcome of erythema migrans after treatment with phenoxymethyl
|
|
penicillin. Scandinavian Journal of
|
|
Infectious Diseases. 2003;
|
|
35(2):129–131 [<a href="https://pubmed.ncbi.nlm.nih.gov/12693565" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12693565</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="ch5.ref14">Berende
|
|
A,
|
|
ter Hofstede
|
|
HJ,
|
|
Donders
|
|
AR,
|
|
van Middendorp
|
|
H,
|
|
Kessels
|
|
RP,
|
|
Adang
|
|
EM
|
|
et al. Persistent Lyme Empiric Antibiotic Study Europe
|
|
(PLEASE)--design of a randomized controlled trial of prolonged
|
|
antibiotic treatment in patients with persistent symptoms attributed
|
|
to Lyme borreliosis. BMC Infectious
|
|
Diseases. 2014;
|
|
14:543 [<a href="/pmc/articles/PMC4203907/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4203907</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25318999" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25318999</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="ch5.ref15">Berger
|
|
BW. Treating
|
|
erythema chronicum migrans of Lyme disease.
|
|
Journal of the American Academy of Dermatology.
|
|
1986;
|
|
15(3):459–463 [<a href="https://pubmed.ncbi.nlm.nih.gov/3093544" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3093544</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="ch5.ref16">Berger
|
|
BW.
|
|
Treatment of erythema chronicum migrans of Lyme
|
|
disease. Annals of the New York Academy of
|
|
Sciences. 1988;
|
|
539:346–351 [<a href="https://pubmed.ncbi.nlm.nih.gov/3190102" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3190102</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="ch5.ref17">Bernardino
|
|
AL,
|
|
Kaushal
|
|
D,
|
|
Philipp
|
|
MT. The
|
|
antibiotics doxycycline and minocycline inhibit the inflammatory
|
|
responses to the Lyme disease spirochete Borrelia
|
|
burgdorferi. Journal of Infectious
|
|
Diseases. 2009;
|
|
199(9):1379–1388 [<a href="/pmc/articles/PMC3697124/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3697124</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19301981" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19301981</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="ch5.ref18">Bhate
|
|
C,
|
|
Schwartz
|
|
RA. Lyme
|
|
disease: Part II. Management and prevention.
|
|
Journal of the American Academy of Dermatology.
|
|
2011;
|
|
64(4):639–653 [<a href="https://pubmed.ncbi.nlm.nih.gov/21414494" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21414494</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="ch5.ref19">Bjark
|
|
PH. Re: No
|
|
prolonged antibiotic therapy for disease attributed to
|
|
borreliosis. Tidsskrift for den Norske
|
|
Laegeforening. 2016;
|
|
136(20):1702–1703 [<a href="https://pubmed.ncbi.nlm.nih.gov/27830900" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27830900</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="ch5.ref20">BMJ Group and the Royal
|
|
Pharmaceutical Society of Great Britain. British
|
|
National Formulary. Available from: <a href="https://www.evidence.nhs.uk/formulary/bnf/current" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.evidence<wbr style="display:inline-block"></wbr>​.nhs.uk/formulary/bnf/current</a> Last
|
|
accessed: 04 April
|
|
2017.</div></dd></dl><dl class="bkr_refwrap"><dt>21.</dt><dd><div class="bk_ref" id="ch5.ref21">BMJ Group and the Royal
|
|
Pharmaceutical Society of Great Britain. British
|
|
National Formulary for Children. Available from: <a href="https://www.evidence.nhs.uk/formulary/bnf/current" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.evidence<wbr style="display:inline-block"></wbr>​.nhs.uk/formulary/bnf/current</a> Last
|
|
accessed: 04 April
|
|
2017.</div></dd></dl><dl class="bkr_refwrap"><dt>22.</dt><dd><div class="bk_ref" id="ch5.ref22">Borg
|
|
R,
|
|
Dotevall
|
|
L,
|
|
Hagberg
|
|
L,
|
|
Maraspin
|
|
V,
|
|
Lotric-Furlan
|
|
S,
|
|
Cimperman
|
|
J
|
|
et al. Intravenous ceftriaxone compared with oral
|
|
doxycycline for the treatment of Lyme
|
|
neuroborreliosis. Scandinavian Journal of
|
|
Infectious Diseases. 2005;
|
|
37(6–7):449–454 [<a href="https://pubmed.ncbi.nlm.nih.gov/16012005" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16012005</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>23.</dt><dd><div class="bk_ref" id="ch5.ref23">Bratton
|
|
RL,
|
|
Whiteside
|
|
JW,
|
|
Hovan
|
|
MJ,
|
|
Engle
|
|
RL,
|
|
Edwards
|
|
FD.
|
|
Diagnosis and treatment of lyme
|
|
disease. Mayo Clinic Proceedings.
|
|
2008;
|
|
83(5):566–571 [<a href="https://pubmed.ncbi.nlm.nih.gov/18452688" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18452688</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>24.</dt><dd><div class="bk_ref" id="ch5.ref24">Bremell
|
|
D,
|
|
Dotevall
|
|
L. Oral
|
|
doxycycline for Lyme neuroborreliosis with symptoms of encephalitis,
|
|
myelitis, vasculitis or intracranial hypertension.
|
|
European Journal of Neurology. 2014;
|
|
21(9):1162–1167 [<a href="https://pubmed.ncbi.nlm.nih.gov/24684211" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24684211</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>25.</dt><dd><div class="bk_ref" id="ch5.ref25">British Infection
|
|
Association. The epidemiology, prevention,
|
|
investigation and treatment of Lyme borreliosis in United Kingdom
|
|
patients: A position statement by the British Infection
|
|
Association. Journal of Infection.
|
|
2011;
|
|
62(5):329–338 [<a href="https://pubmed.ncbi.nlm.nih.gov/21421007" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21421007</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>26.</dt><dd><div class="bk_ref" id="ch5.ref26">Butler
|
|
T,
|
|
Jones
|
|
PK,
|
|
Wallace
|
|
CK. Borrelia
|
|
recurrentis infection: single-dose antibiotic regimens and
|
|
management of the Jarisch-Herxheimer reaction.
|
|
Journal of Infectious Diseases. 1978;
|
|
137(5):573–577 [<a href="https://pubmed.ncbi.nlm.nih.gov/659915" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 659915</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>27.</dt><dd><div class="bk_ref" id="ch5.ref27">Cadavid
|
|
D,
|
|
Auwaerter
|
|
PG,
|
|
Rumbaugh
|
|
J,
|
|
Gelderblom
|
|
H.
|
|
Antibiotics for the neurological complications of
|
|
Lyme disease. Cochrane Database of
|
|
Systematic Reviews
|
|
2016, Issue 12. Art. No.: CD006978. DOI:
|
|
10.1002/14651858.CD006978.pub2. [<a href="/pmc/articles/PMC6463975/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6463975</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27931077" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27931077</span></a>] [<a href="http://dx.crossref.org/10.1002/14651858.CD006978.pub2" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd></dl><dl class="bkr_refwrap"><dt>28.</dt><dd><div class="bk_ref" id="ch5.ref28">Canadian Paediatric
|
|
Society. How to diagnose and treat Lyme
|
|
disease in children. Infectious Diseases and Immunization Committee,
|
|
Canadian Paediatric Society. CMAJ.
|
|
1992;
|
|
147(2):169–178 [<a href="/pmc/articles/PMC1336159/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1336159</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1623463" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1623463</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>29.</dt><dd><div class="bk_ref" id="ch5.ref29">Chapman
|
|
AL,
|
|
Dixon
|
|
S,
|
|
Andrews
|
|
D,
|
|
Lillie
|
|
PJ,
|
|
Bazaz
|
|
R,
|
|
Patchett
|
|
JD. Clinical
|
|
efficacy and cost-effectiveness of outpatient parenteral antibiotic
|
|
therapy (OPAT): a UK perspective. Journal of
|
|
Antimicrobial Chemotherapy. 2009;
|
|
64(6):1316–1324 [<a href="https://pubmed.ncbi.nlm.nih.gov/19767623" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19767623</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>30.</dt><dd><div class="bk_ref" id="ch5.ref30">Chen
|
|
J,
|
|
Field
|
|
JA,
|
|
Glickstein
|
|
L,
|
|
Molloy
|
|
PJ,
|
|
Huber
|
|
BT,
|
|
Steere
|
|
AC.
|
|
Association of antibiotic treatment-resistant Lyme
|
|
arthritis with T cell responses to dominant epitopes of outer
|
|
surface protein a of Borrelia burgdorferi.
|
|
Arthritis and Rheumatism. 1999;
|
|
42(9):1813–1822 [<a href="https://pubmed.ncbi.nlm.nih.gov/10513794" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10513794</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>31.</dt><dd><div class="bk_ref" id="ch5.ref31">Choo-Kang
|
|
C,
|
|
Tang
|
|
E,
|
|
Mattappallil
|
|
A. The
|
|
treatment of early lyme disease. US
|
|
Pharmacist. 2010;
|
|
35(9):41–48</div></dd></dl><dl class="bkr_refwrap"><dt>32.</dt><dd><div class="bk_ref" id="ch5.ref32">Christian
|
|
CL.
|
|
Management of asymptomatic Borrelia burgdorferi
|
|
infection. Arthritis and
|
|
Rheumatism. 1992;
|
|
35(11):1395 [<a href="https://pubmed.ncbi.nlm.nih.gov/1445461" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1445461</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>33.</dt><dd><div class="bk_ref" id="ch5.ref33">Cimmino
|
|
MA.
|
|
Recognition and management of bacterial
|
|
arthritis. Drugs.
|
|
1997;
|
|
54(1):50–60 [<a href="https://pubmed.ncbi.nlm.nih.gov/9211079" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9211079</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>34.</dt><dd><div class="bk_ref" id="ch5.ref34">Cimmino
|
|
MA,
|
|
Accardo
|
|
S. Long term
|
|
treatment of chronic Lyme arthritis with benzathine
|
|
penicillin. Annals of the Rheumatic
|
|
Diseases. 1992;
|
|
51(8):1007–1008 [<a href="/pmc/articles/PMC1004816/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1004816</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1417107" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1417107</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>35.</dt><dd><div class="bk_ref" id="ch5.ref35">Cimperman
|
|
J,
|
|
Maraspin
|
|
V,
|
|
Lotric-Furlan
|
|
S,
|
|
Ruzic-Sabljic
|
|
E,
|
|
Strle
|
|
F. Lyme
|
|
meningitis: a one-year follow up controlled study.
|
|
Wiener Klinische Wochenschrift. 1999;
|
|
111(22–23):961–963 [<a href="https://pubmed.ncbi.nlm.nih.gov/10666809" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10666809</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>36.</dt><dd><div class="bk_ref" id="ch5.ref36">Coblyn
|
|
JS,
|
|
Taylor
|
|
P. Treatment
|
|
of chronic Lyme arthritis with hydroxychloroquine.
|
|
Arthritis and Rheumatism. 1981;
|
|
24(12):1567–1569 [<a href="https://pubmed.ncbi.nlm.nih.gov/7326069" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7326069</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>37.</dt><dd><div class="bk_ref" id="ch5.ref37">Commercial Medicines Unit
|
|
(CMU), Department of Health. Electronic market
|
|
information tool (EMIT). 2011. Available from:
|
|
<a href="http://cmu.dh.gov.uk/electronic-market-information-tool-emit/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://cmu<wbr style="display:inline-block"></wbr>​.dh.gov.uk<wbr style="display:inline-block"></wbr>​/electronic-market-information-tool-emit/</a>
|
|
Last accessed: 4 April
|
|
2017.</div></dd></dl><dl class="bkr_refwrap"><dt>38.</dt><dd><div class="bk_ref" id="ch5.ref38">Committee on Infectious
|
|
Diseases. Erratum: Treatment of lyme
|
|
borreliosis (Pediatrics (July 1991) 88
|
|
(7–19)). Pediatrics.
|
|
1991;
|
|
88(4):840</div></dd></dl><dl class="bkr_refwrap"><dt>39.</dt><dd><div class="bk_ref" id="ch5.ref39">Cuisset
|
|
T,
|
|
Hamilos
|
|
M,
|
|
Vanderheyden
|
|
M. Coronary
|
|
aneurysm in Lyme disease: treatment by covered
|
|
stent. International Journal of
|
|
Cardiology. 2008;
|
|
128(2):e72–e73 [<a href="https://pubmed.ncbi.nlm.nih.gov/17692941" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17692941</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>40.</dt><dd><div class="bk_ref" id="ch5.ref40">Curtis
|
|
L,
|
|
Burns
|
|
A. Unit costs of
|
|
health and social care 2016.
|
|
Canterbury. Personal
|
|
Social Services Research Unit University of Kent,
|
|
2016. Available from: <a href="http://www.pssru.ac.uk/project-pages/unit-costs/2016/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.pssru.ac.uk<wbr style="display:inline-block"></wbr>​/project-pages/unit-costs/2016/</a></div></dd></dl><dl class="bkr_refwrap"><dt>41.</dt><dd><div class="bk_ref" id="ch5.ref41">Dattwyler
|
|
RJ,
|
|
Grunwaldt
|
|
E,
|
|
Luft
|
|
BJ.
|
|
Clarithromycin in treatment of early Lyme disease: a
|
|
pilot study. Antimicrobial Agents and
|
|
Chemotherapy. 1996;
|
|
40(2):468–469 [<a href="/pmc/articles/PMC163136/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC163136</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8834900" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8834900</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>42.</dt><dd><div class="bk_ref" id="ch5.ref42">Dattwyler
|
|
RJ,
|
|
Halperin
|
|
JJ. Failure
|
|
of tetracycline therapy in early Lyme disease.
|
|
Arthritis and Rheumatism. 1987;
|
|
30(4):448–450 [<a href="https://pubmed.ncbi.nlm.nih.gov/3580012" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3580012</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>43.</dt><dd><div class="bk_ref" id="ch5.ref43">Dattwyler
|
|
RJ,
|
|
Halperin
|
|
JJ,
|
|
Volkman
|
|
DJ,
|
|
Luft
|
|
BJ.
|
|
Treatment of late Lyme borreliosis - randomised
|
|
comparison of ceftriaxone and penicillin.
|
|
Lancet. 1988;
|
|
1(8596):1191–1194 [<a href="https://pubmed.ncbi.nlm.nih.gov/2897008" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2897008</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>44.</dt><dd><div class="bk_ref" id="ch5.ref44">Dattwyler
|
|
RJ,
|
|
Wormser
|
|
GP,
|
|
Rush
|
|
TJ,
|
|
Finkel
|
|
MF,
|
|
Schoen
|
|
RT,
|
|
Grunwaldt
|
|
E
|
|
et al. A comparison of two treatment regimens of
|
|
ceftriaxone in late Lyme disease. Wiener
|
|
Klinische Wochenschrift. 2005;
|
|
117(11–12):393–397 [<a href="https://pubmed.ncbi.nlm.nih.gov/16053194" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16053194</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>45.</dt><dd><div class="bk_ref" id="ch5.ref45">Department of
|
|
Health. NHS reference costs 2015–16.
|
|
2016. Available from: <a href="https://www.gov.uk/government/publications/nhs-reference-costs-collection-guidance-for-2015-to-2016" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.gov.uk/government<wbr style="display:inline-block"></wbr>​/publications<wbr style="display:inline-block"></wbr>​/nhs-reference-costs-collection-guidance-for-2015-to-2016</a>
|
|
Last accessed: 4 April
|
|
2017.</div></dd></dl><dl class="bkr_refwrap"><dt>46.</dt><dd><div class="bk_ref" id="ch5.ref46">Dersch
|
|
R,
|
|
Freitag
|
|
MH,
|
|
Schmidt
|
|
S,
|
|
Sommer
|
|
H,
|
|
Rauer
|
|
S,
|
|
Meerpohl
|
|
JJ. Efficacy
|
|
and safety of pharmacological treatments for acute Lyme
|
|
neuroborreliosis - a systematic review.
|
|
European Journal of Neurology. 2015;
|
|
22(9):1249–1259 [<a href="https://pubmed.ncbi.nlm.nih.gov/26058321" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26058321</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>47.</dt><dd><div class="bk_ref" id="ch5.ref47">Dersch
|
|
R,
|
|
Freitag
|
|
MH,
|
|
Schmidt
|
|
S,
|
|
Sommer
|
|
H,
|
|
Rucker
|
|
G,
|
|
Rauer
|
|
S
|
|
et al. Efficacy and safety of pharmacological
|
|
treatments for neuroborreliosis--protocol for a systematic
|
|
review. Systems Review.
|
|
2014;
|
|
3:117 [<a href="/pmc/articles/PMC4207098/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4207098</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25336085" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25336085</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>48.</dt><dd><div class="bk_ref" id="ch5.ref48">Dersch
|
|
R,
|
|
Rauer
|
|
S. Treatment
|
|
and long-term outcome of Lyme neuroborreliosis.
|
|
Aktuelle neurologie. 2017;
|
|
43(10):608–614</div></dd></dl><dl class="bkr_refwrap"><dt>49.</dt><dd><div class="bk_ref" id="ch5.ref49">Dersch
|
|
R,
|
|
Sommer
|
|
H,
|
|
Rauer
|
|
S,
|
|
Meerpohl
|
|
JJ.
|
|
Prevalence and spectrum of residual symptoms in Lyme
|
|
neuroborreliosis after pharmacological treatment: a systematic
|
|
review. Journal of Neurology.
|
|
2016;
|
|
263(1):17–24 [<a href="https://pubmed.ncbi.nlm.nih.gov/26459093" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26459093</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>50.</dt><dd><div class="bk_ref" id="ch5.ref50">Dhoot
|
|
DS,
|
|
Martin
|
|
DF,
|
|
Srivastava
|
|
SK.
|
|
Pediatric infectious posterior
|
|
uveitis. International Ophthalmology
|
|
Clinics. 2011;
|
|
51(1):113–128 [<a href="https://pubmed.ncbi.nlm.nih.gov/21139480" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21139480</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>51.</dt><dd><div class="bk_ref" id="ch5.ref51">Dinser
|
|
R,
|
|
Jendro
|
|
MC,
|
|
Schnarr
|
|
S,
|
|
Zeidler
|
|
H.
|
|
Antibiotic treatment of Lyme borreliosis: what is the
|
|
evidence?
|
|
Annals of the Rheumatic Diseases. 2005;
|
|
64(4):519–523 [<a href="/pmc/articles/PMC1755466/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1755466</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15769910" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15769910</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>52.</dt><dd><div class="bk_ref" id="ch5.ref52">Dotevall
|
|
L,
|
|
Alestig
|
|
K,
|
|
Hanner
|
|
P,
|
|
Norkrans
|
|
G,
|
|
Hagberg
|
|
L. The use
|
|
of doxycycline in nervous system Borrelia burgdorferi
|
|
infection. Scandinavian Journal of
|
|
Infectious Diseases Supplement. 1988;
|
|
53:74–79 [<a href="https://pubmed.ncbi.nlm.nih.gov/3166545" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3166545</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>53.</dt><dd><div class="bk_ref" id="ch5.ref53">Eliassen
|
|
KE,
|
|
Berild
|
|
D,
|
|
Reiso
|
|
H,
|
|
Grude
|
|
N,
|
|
Christophersen
|
|
KS,
|
|
Finckenhagen
|
|
C
|
|
et al. Incidence and antibiotic treatment of erythema
|
|
migrans in Norway 2005–2009. Ticks
|
|
and Tick-Borne Diseases. 2017;
|
|
8(1):1–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/27475874" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27475874</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>54.</dt><dd><div class="bk_ref" id="ch5.ref54">Eliassen
|
|
KE,
|
|
Hjetland
|
|
R,
|
|
Reiso
|
|
H,
|
|
Lindbaek
|
|
M,
|
|
Tschudi-Madsen
|
|
H. Symptom
|
|
load and general function among patients with erythema migrans: a
|
|
prospective study with a 1-year follow-up after antibiotic treatment
|
|
in Norwegian general practice. Scandinavian
|
|
Journal of Primary Health Care. 2017;
|
|
35(1):75–83 [<a href="/pmc/articles/PMC5361422/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5361422</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28277054" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28277054</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>55.</dt><dd><div class="bk_ref" id="ch5.ref55">Eppes
|
|
SC.
|
|
Diagnosis, treatment, and prevention of Lyme disease
|
|
in children. Pediatric Drugs.
|
|
2003;
|
|
5(6):363–372 [<a href="https://pubmed.ncbi.nlm.nih.gov/12765486" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12765486</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>56.</dt><dd><div class="bk_ref" id="ch5.ref56">Esposito
|
|
S,
|
|
Baggi
|
|
E,
|
|
Villani
|
|
A,
|
|
Norbedo
|
|
S,
|
|
Pellegrini
|
|
G,
|
|
Bozzola
|
|
E
|
|
et al. Management of paediatric Lyme disease in
|
|
non-endemic and endemic areas: data from the registry of the Italian
|
|
Society for Pediatric Infectious Diseases.
|
|
European Journal of Clinical Microbiology and Infectious
|
|
Diseases. 2013;
|
|
32(4):523–529 [<a href="https://pubmed.ncbi.nlm.nih.gov/23109197" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23109197</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>57.</dt><dd><div class="bk_ref" id="ch5.ref57">Fallon
|
|
BA,
|
|
Keilp
|
|
JG,
|
|
Corbera
|
|
KM,
|
|
Petkova
|
|
E,
|
|
Britton
|
|
CB,
|
|
Dwyer
|
|
E
|
|
et al. A randomized, placebo-controlled trial of
|
|
repeated IV antibiotic therapy for Lyme
|
|
encephalopathy. Neurology.
|
|
2008;
|
|
70(13):992–1003 [<a href="https://pubmed.ncbi.nlm.nih.gov/17928580" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17928580</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>58.</dt><dd><div class="bk_ref" id="ch5.ref58">Fallon
|
|
BA,
|
|
Tager
|
|
F,
|
|
Fein
|
|
L,
|
|
Liegner
|
|
K,
|
|
Keilp
|
|
J,
|
|
Weiss
|
|
N
|
|
et al. Repeated antibiotic treatment in chronic Lyme
|
|
disease. Journal of Spirochetal and
|
|
Tick-borne Diseases. 1999;
|
|
6(4):94–102</div></dd></dl><dl class="bkr_refwrap"><dt>59.</dt><dd><div class="bk_ref" id="ch5.ref59">Galev
|
|
A,
|
|
Zvetkov
|
|
V,
|
|
Genov
|
|
K. Pulse
|
|
therapy with ceftriaxone on Lyme neuroborreliosis.
|
|
Problems of Infectious and Parasitic Diseases.
|
|
2005;
|
|
33(1):15–17</div></dd></dl><dl class="bkr_refwrap"><dt>60.</dt><dd><div class="bk_ref" id="ch5.ref60">Garkowski
|
|
A,
|
|
Zajkowska
|
|
J,
|
|
Zajkowska
|
|
A,
|
|
Kulakowska
|
|
A,
|
|
Zajkowska
|
|
O,
|
|
Kubas
|
|
B
|
|
et al. Cerebrovascular manifestations of Lyme
|
|
neuroborreliosis-a systematic review of published
|
|
cases. Frontiers in Neurology.
|
|
2017;
|
|
8:146 [<a href="/pmc/articles/PMC5397664/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5397664</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28473801" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28473801</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>61.</dt><dd><div class="bk_ref" id="ch5.ref61">Gasser
|
|
R,
|
|
Reisinger
|
|
E,
|
|
Eber
|
|
B,
|
|
Pokan
|
|
R,
|
|
Seinost
|
|
G,
|
|
Bergloff
|
|
J
|
|
et al. Cases of Lyme borreliosis resistant to
|
|
conventional treatment: improved symptoms with cephalosporin plus
|
|
specific beta-lactamase inhibition.
|
|
Microbial Drug Resistance. 1995;
|
|
1(4):341–344 [<a href="https://pubmed.ncbi.nlm.nih.gov/9158807" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9158807</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>62.</dt><dd><div class="bk_ref" id="ch5.ref62">Gasser
|
|
R,
|
|
Reisinger
|
|
E,
|
|
Sedaj
|
|
B,
|
|
Horvarth
|
|
R,
|
|
Seinost
|
|
G,
|
|
Keplinger
|
|
A
|
|
et al. Oral treatment of late Lyme borreliosis with a
|
|
combination of roxithromycin and co-trimoxazole--a pilot study on 18
|
|
patients. Acta Medica Austriaca.
|
|
1996;
|
|
23(3):99–101 [<a href="https://pubmed.ncbi.nlm.nih.gov/8798283" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8798283</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>63.</dt><dd><div class="bk_ref" id="ch5.ref63">Gasser
|
|
R,
|
|
Wendelin
|
|
I,
|
|
Reisinger
|
|
E,
|
|
Bergloff
|
|
J,
|
|
Feigl
|
|
B,
|
|
Schafhalter
|
|
I
|
|
et al. Roxithromycin in the treatment of Lyme
|
|
disease--update and perspectives.
|
|
Infection. 1995; 23
|
|
(Suppl.1):S39–43 [<a href="https://pubmed.ncbi.nlm.nih.gov/7782115" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7782115</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>64.</dt><dd><div class="bk_ref" id="ch5.ref64">Gerber
|
|
MA,
|
|
Shapiro
|
|
ED,
|
|
Burke
|
|
GS,
|
|
Parcells
|
|
VJ,
|
|
Bell
|
|
GL. Lyme
|
|
disease in children in southeastern Connecticut. Pediatric Lyme
|
|
Disease Study Group. New England Journal of
|
|
Medicine. 1996;
|
|
335(17):1270–1274 [<a href="https://pubmed.ncbi.nlm.nih.gov/8857006" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8857006</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>65.</dt><dd><div class="bk_ref" id="ch5.ref65">Gillies
|
|
M,
|
|
Ranakusuma
|
|
A,
|
|
Hoffmann
|
|
T,
|
|
Thorning
|
|
S,
|
|
McGuire
|
|
T,
|
|
Glasziou
|
|
P
|
|
et al. Common harms from amoxicillin: a systematic
|
|
review and meta-analysis of randomized placebo-controlled trials for
|
|
any indication. CMAJ.
|
|
2015;
|
|
187(1):E21–E31 [<a href="/pmc/articles/PMC4284189/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4284189</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25404399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25404399</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>66.</dt><dd><div class="bk_ref" id="ch5.ref66">Goodwin
|
|
SD,
|
|
Sproat
|
|
TT,
|
|
Russell
|
|
WL.
|
|
Management of Lyme disease.
|
|
Clinical Pharmacy. 1990;
|
|
9(3):192–205 [<a href="https://pubmed.ncbi.nlm.nih.gov/2180624" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2180624</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>67.</dt><dd><div class="bk_ref" id="ch5.ref67">Hansen
|
|
K,
|
|
Hovmark
|
|
A,
|
|
Lebech
|
|
AM,
|
|
Lebech
|
|
K,
|
|
Olsson
|
|
I,
|
|
Halkier-Sørensen
|
|
L
|
|
et al. Roxithromycin in Lyme borreliosis: discrepant
|
|
results of an in vitro and in vivo animal susceptibility study and a
|
|
clinical trial in patients with erythema migrans.
|
|
Acta Dermato-Venereologica. 1992;
|
|
72(4):297–300 [<a href="https://pubmed.ncbi.nlm.nih.gov/1357894" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1357894</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>68.</dt><dd><div class="bk_ref" id="ch5.ref68">Hassler
|
|
D,
|
|
Zoller
|
|
L,
|
|
Haude
|
|
M,
|
|
Hufnagel
|
|
HD,
|
|
Heinrich
|
|
F,
|
|
Sonntag
|
|
HG.
|
|
Cefotaxime versus penicillin in the late stage of
|
|
Lyme disease: prospective, randomized therapeutic
|
|
study. Infection.
|
|
1990;
|
|
18(1):16–20 [<a href="https://pubmed.ncbi.nlm.nih.gov/2179134" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2179134</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>69.</dt><dd><div class="bk_ref" id="ch5.ref69">Horton
|
|
DB,
|
|
Taxter
|
|
AJ,
|
|
Groh
|
|
B,
|
|
Sherry
|
|
DD,
|
|
Rose
|
|
CD. Clinical
|
|
and treatment factors associated with antibiotic-refractory Lyme
|
|
arthritis in children. Arthritis and
|
|
Rheumatology. 2017;
|
|
68(S10):3140–3143</div></dd></dl><dl class="bkr_refwrap"><dt>70.</dt><dd><div class="bk_ref" id="ch5.ref70">Hu
|
|
LT,
|
|
Klempner
|
|
MS. Update
|
|
on the prevention, diagnosis, and treatment of Lyme
|
|
disease. Advances in Internal
|
|
Medicine. 2001;
|
|
46:247–275 [<a href="https://pubmed.ncbi.nlm.nih.gov/11270961" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11270961</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>71.</dt><dd><div class="bk_ref" id="ch5.ref71">Inboriboon
|
|
PC. Early
|
|
recognition and management of Lyme carditis.
|
|
International Journal of Emergency Medicine.
|
|
2010;
|
|
3(4):489–490 [<a href="/pmc/articles/PMC3047882/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3047882</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21373337" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21373337</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>72.</dt><dd><div class="bk_ref" id="ch5.ref72">Kaplan
|
|
RF,
|
|
Trevino
|
|
RP,
|
|
Johnson
|
|
GM,
|
|
Levy
|
|
L,
|
|
Dornbush
|
|
R,
|
|
Hu
|
|
LT
|
|
et al. Cognitive function in post-treatment Lyme disease: do
|
|
additional antibiotics help? Neurology. 2003;
|
|
60(12):1916–1922 [<a href="https://pubmed.ncbi.nlm.nih.gov/12821733" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12821733</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>73.</dt><dd><div class="bk_ref" id="ch5.ref73">Karkkonen
|
|
K,
|
|
Stiernstedt
|
|
SH,
|
|
Karlsson
|
|
M. Follow-up
|
|
of patients treated with oral doxycycline for Lyme
|
|
neuroborreliosis. Scandinavian Journal of
|
|
Infectious Diseases. 2001;
|
|
33(4):259–262 [<a href="https://pubmed.ncbi.nlm.nih.gov/11345216" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11345216</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>74.</dt><dd><div class="bk_ref" id="ch5.ref74">Karlsson
|
|
M,
|
|
Hammers
|
|
S,
|
|
Nilsson-Ehle
|
|
I,
|
|
Malmborg
|
|
AS,
|
|
Wretlind
|
|
B.
|
|
Concentrations of doxycycline and penicillin G in
|
|
sera and cerebrospinal fluid of patients treated for
|
|
neuroborreliosis. Antimicrobial Agents and
|
|
Chemotherapy. 1996;
|
|
40(5):1104–1107 [<a href="/pmc/articles/PMC163273/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC163273</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8723448" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8723448</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>75.</dt><dd><div class="bk_ref" id="ch5.ref75">Kersten
|
|
A,
|
|
Poitschek
|
|
C,
|
|
Rauch
|
|
S,
|
|
Aberer
|
|
E. Effects
|
|
of penicillin, ceftriaxone, and doxycycline on morphology of
|
|
Borrelia burgdorferi. Antimicrobial Agents
|
|
and Chemotherapy. 1995;
|
|
39(5):1127–1133 [<a href="/pmc/articles/PMC162695/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC162695</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7625800" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7625800</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>76.</dt><dd><div class="bk_ref" id="ch5.ref76">Kilic
|
|
Muftuoglu
|
|
I,
|
|
Aydin Akova
|
|
Y,
|
|
Gur Gungor
|
|
S. A case of
|
|
Lyme disease accompanied by uveitis and white dot
|
|
syndrome. Turkish Journal of
|
|
Ophthalmology. 2016;
|
|
46(5):241–243 [<a href="/pmc/articles/PMC5200838/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5200838</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28058168" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28058168</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>77.</dt><dd><div class="bk_ref" id="ch5.ref77">Klempner
|
|
MS.
|
|
Controlled trials of antibiotic treatment in patients
|
|
with post-treatment chronic Lyme disease.
|
|
Vector Borne and Zoonotic Diseases.
|
|
2002;
|
|
2(4):255–263 [<a href="https://pubmed.ncbi.nlm.nih.gov/12804167" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12804167</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>78.</dt><dd><div class="bk_ref" id="ch5.ref78">Klempner
|
|
MS,
|
|
Baker
|
|
PJ,
|
|
Shapiro
|
|
ED,
|
|
Marques
|
|
A,
|
|
Dattwyler
|
|
RJ,
|
|
Halperin
|
|
JJ
|
|
et al. Treatment trials for post-lyme disease symptoms
|
|
revisited. American Journal of
|
|
Medicine. 2013;
|
|
126(8):665–669 [<a href="/pmc/articles/PMC4075423/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4075423</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23764268" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23764268</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>79.</dt><dd><div class="bk_ref" id="ch5.ref79">Korenberg
|
|
EI,
|
|
Vorobyeva
|
|
NN,
|
|
Moskvitina
|
|
HG,
|
|
Gorban
|
|
Ln.
|
|
Prevention of borreliosis in persons bitten by
|
|
infected ticks. Infection.
|
|
1996;
|
|
24(2):187–189 [<a href="https://pubmed.ncbi.nlm.nih.gov/8740120" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8740120</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>80.</dt><dd><div class="bk_ref" id="ch5.ref80">Kowalski
|
|
TJ,
|
|
Berth
|
|
WL,
|
|
Mathiason
|
|
MA,
|
|
Agger
|
|
WA. Oral
|
|
antibiotic treatment and long-term outcomes of Lyme facial nerve
|
|
palsy. Infection.
|
|
2011;
|
|
39(3):239–245 [<a href="https://pubmed.ncbi.nlm.nih.gov/21523405" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21523405</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>81.</dt><dd><div class="bk_ref" id="ch5.ref81">Kowalski
|
|
TJ,
|
|
Tata
|
|
S,
|
|
Berth
|
|
W,
|
|
Mathiason
|
|
MA,
|
|
Agger
|
|
WA.
|
|
Antibiotic treatment duration and long-term outcomes
|
|
of patients with early Lyme disease from a Lyme disease-hyperendemic
|
|
area. Clinical Infectious Diseases.
|
|
2010;
|
|
50(4):512–520 [<a href="https://pubmed.ncbi.nlm.nih.gov/20070237" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20070237</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>82.</dt><dd><div class="bk_ref" id="ch5.ref82">Krbkova
|
|
L,
|
|
Stanek
|
|
G. Therapy
|
|
of Lyme borreliosis in children.
|
|
Infection. 1996;
|
|
24(2):170–173 [<a href="https://pubmed.ncbi.nlm.nih.gov/8740116" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8740116</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>83.</dt><dd><div class="bk_ref" id="ch5.ref83">Kuhn
|
|
M,
|
|
Grave
|
|
S,
|
|
Bransfield
|
|
R,
|
|
Harris
|
|
S. Long term
|
|
antibiotic therapy may be an effective treatment for children
|
|
co-morbid with Lyme disease and autism spectrum
|
|
disorder. Medical Hypotheses.
|
|
2012;
|
|
78(5):606–615 [<a href="https://pubmed.ncbi.nlm.nih.gov/22361005" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22361005</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>84.</dt><dd><div class="bk_ref" id="ch5.ref84">Laasila
|
|
K,
|
|
Laasonen
|
|
L,
|
|
Leirisalo-Repo
|
|
M.
|
|
Antibiotic treatment and long term prognosis of
|
|
reactive arthritis. Annals of the Rheumatic
|
|
Diseases. 2003;
|
|
62(7):655–658 [<a href="/pmc/articles/PMC1754599/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1754599</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12810429" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12810429</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>85.</dt><dd><div class="bk_ref" id="ch5.ref85">Lantos
|
|
PM,
|
|
Brinkerhoff
|
|
RJ,
|
|
Wormser
|
|
GP,
|
|
Clemen
|
|
R. Empiric
|
|
antibiotic treatment of erythema migrans-like skin lesions as a
|
|
function of geography: a clinical and cost effectiveness modeling
|
|
study. Vector Borne and Zoonotic
|
|
Diseases. 2013;
|
|
13(12):877–883 [<a href="/pmc/articles/PMC3868279/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3868279</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24107201" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24107201</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>86.</dt><dd><div class="bk_ref" id="ch5.ref86">Lauhio
|
|
A,
|
|
Konttinen
|
|
YT,
|
|
Salo
|
|
T,
|
|
Tschesche
|
|
H,
|
|
Lahdevirta
|
|
J,
|
|
Woessner
|
|
FJ
|
|
et al. Placebo-controlled study of the effects of
|
|
three-month lymecyclille treatment on serum matrix
|
|
metalloproteinases in reactive arthritis.
|
|
Annals of the New York Academy of Sciences.
|
|
1994;
|
|
732:424–426 [<a href="https://pubmed.ncbi.nlm.nih.gov/7978828" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7978828</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>87.</dt><dd><div class="bk_ref" id="ch5.ref87">Lauhio
|
|
A,
|
|
Leirisalo-Repo
|
|
M,
|
|
Lahdevirta
|
|
J,
|
|
Saikku
|
|
P,
|
|
Repo
|
|
H.
|
|
Double-blind, placebo-controlled study of three-month
|
|
treatment with lymecycline in reactive arthritis, with special
|
|
reference to Chlamydia arthritis. Arthritis
|
|
and Rheumatism. 1991;
|
|
34(1):6–14 [<a href="https://pubmed.ncbi.nlm.nih.gov/1670621" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1670621</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>88.</dt><dd><div class="bk_ref" id="ch5.ref88">Liegner
|
|
KB.
|
|
Minocycline in Lyme disease.
|
|
Journal of the American Academy of Dermatology.
|
|
1992; 26(2 Pt
|
|
1):263–264 [<a href="https://pubmed.ncbi.nlm.nih.gov/1552067" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1552067</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>89.</dt><dd><div class="bk_ref" id="ch5.ref89">Lipsker
|
|
D,
|
|
Antoni-Bach
|
|
N,
|
|
Hansmann
|
|
Y,
|
|
Jaulhac
|
|
B. Long-term
|
|
prognosis of patients treated for erythema migrans in
|
|
France. British Journal of
|
|
Dermatology. 2002;
|
|
146(5):872–876 [<a href="https://pubmed.ncbi.nlm.nih.gov/12000387" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12000387</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>90.</dt><dd><div class="bk_ref" id="ch5.ref90">Ljostad
|
|
U,
|
|
Eikeland
|
|
R,
|
|
Midgard
|
|
R,
|
|
Skogvoll
|
|
E,
|
|
Skarpass
|
|
T,
|
|
Berg
|
|
A. Oral
|
|
doxycycline vs. IV centriaxone for European Lyme neuro-borreliosis.
|
|
A double-blind, randomized controlled clinical
|
|
trial. European Journal of Neurology.
|
|
2008; 15:(Suppl
|
|
3):338–389 [<a href="https://pubmed.ncbi.nlm.nih.gov/18567539" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18567539</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>91.</dt><dd><div class="bk_ref" id="ch5.ref91">Loewen
|
|
PS,
|
|
Marra
|
|
CA,
|
|
Marra
|
|
F.
|
|
Systematic review of the treatment of early Lyme
|
|
disease
|
|
Drugs. 1999;
|
|
57(2):157–173 [<a href="https://pubmed.ncbi.nlm.nih.gov/10188758" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10188758</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>92.</dt><dd><div class="bk_ref" id="ch5.ref92">Loewen
|
|
PS,
|
|
Marra
|
|
CA,
|
|
Marra
|
|
F. Erratum:
|
|
Systemic review of the treatment of early Lyme disease (Drugs (1999)
|
|
57 (2) (157–173)). Drugs.
|
|
2000;
|
|
59(3):476 [<a href="https://pubmed.ncbi.nlm.nih.gov/10188758" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10188758</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>93.</dt><dd><div class="bk_ref" id="ch5.ref93">Luft
|
|
BJ,
|
|
Halperin
|
|
JJ,
|
|
Volkman
|
|
DJ,
|
|
Dattwyler
|
|
RJ.
|
|
Ceftriaxone -an effective treatment of late Lyme
|
|
borreliosis. Journal of
|
|
Chemotherapy. 1989;
|
|
1:(Suppl
|
|
4):917–919 [<a href="https://pubmed.ncbi.nlm.nih.gov/16312703" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16312703</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>94.</dt><dd><div class="bk_ref" id="ch5.ref94">Luft
|
|
BJ,
|
|
Volkman
|
|
DJ,
|
|
Halperin
|
|
JJ,
|
|
Dattwyler
|
|
RJ. New
|
|
chemotherapeutic approaches in the treatment of Lyme
|
|
borreliosis. Annals of the New York Academy
|
|
of Sciences. 1988;
|
|
539:352–361 [<a href="https://pubmed.ncbi.nlm.nih.gov/3056203" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3056203</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>95.</dt><dd><div class="bk_ref" id="ch5.ref95">Maraspin
|
|
V,
|
|
Cimperman
|
|
J,
|
|
Lotric-Furlan
|
|
S,
|
|
Pleterski-Rigler
|
|
D,
|
|
Strle
|
|
F. Treatment
|
|
of erythema migrans in pregnancy. Clinical
|
|
Infectious Diseases. 1996;
|
|
22(5):788–793 [<a href="https://pubmed.ncbi.nlm.nih.gov/8722932" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8722932</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>96.</dt><dd><div class="bk_ref" id="ch5.ref96">Maraspin
|
|
V,
|
|
Cimperman
|
|
J,
|
|
Lotric-Furlan
|
|
S,
|
|
Pleterski-Rigler
|
|
D,
|
|
Strle
|
|
F. Erythema
|
|
migrans in pregnancy. Wiener Klinische
|
|
Wochenschrift. 1999;
|
|
111(22–23):933–940 [<a href="https://pubmed.ncbi.nlm.nih.gov/10666804" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10666804</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>97.</dt><dd><div class="bk_ref" id="ch5.ref97">Maraspin
|
|
V,
|
|
Cimperman
|
|
J,
|
|
Lotric-Furlan
|
|
S,
|
|
Ruzic-Sabljic
|
|
E,
|
|
Jurca
|
|
T,
|
|
Picken
|
|
RN
|
|
et al. Solitary borrelial lymphocytoma in adult
|
|
patients. Wiener Klinische
|
|
Wochenschrift. 2002;
|
|
114(13–14):515–523 [<a href="https://pubmed.ncbi.nlm.nih.gov/12422593" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12422593</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>98.</dt><dd><div class="bk_ref" id="ch5.ref98">Maraspin
|
|
V,
|
|
Lotric-Furlan
|
|
S,
|
|
Cimperman
|
|
J,
|
|
Ruzic-Sabljic
|
|
E,
|
|
Strle
|
|
F. Erythema
|
|
migrans in the immunocompromised host.
|
|
Wiener Klinische Wochenschrift. 1999;
|
|
111(22–23):923–932 [<a href="https://pubmed.ncbi.nlm.nih.gov/10666803" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10666803</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>99.</dt><dd><div class="bk_ref" id="ch5.ref99">Maraspin
|
|
V,
|
|
Lotric-Furlan
|
|
S,
|
|
Strle
|
|
F.
|
|
Development of erythema migrans in spite of treatment
|
|
with antibiotics after a tick bite. Wiener
|
|
Klinische Wochenschrift. 2002;
|
|
114(13–14):616–619 [<a href="https://pubmed.ncbi.nlm.nih.gov/12422612" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12422612</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>100.</dt><dd><div class="bk_ref" id="ch5.ref100">Maraspin
|
|
V,
|
|
Ruzic-Sabljic
|
|
E,
|
|
Strle
|
|
F,
|
|
Cimperman
|
|
J,
|
|
Jereb
|
|
M,
|
|
Preac-Mursic
|
|
V.
|
|
Persistence of Borrelia burgdorferi after treatment
|
|
with antibiotics. Alpe Adria Microbiology
|
|
Journal. 1995;
|
|
4(3):211–216</div></dd></dl><dl class="bkr_refwrap"><dt>101.</dt><dd><div class="bk_ref" id="ch5.ref101">Marks
|
|
CM,
|
|
Nawn
|
|
JE,
|
|
Caplow
|
|
JA.
|
|
Antibiotic treatment for chronic Lyme disease -say no
|
|
to the DRESS. JAMA Internal
|
|
Medicine. 2016;
|
|
176(12):1745–1746 [<a href="https://pubmed.ncbi.nlm.nih.gov/27775763" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27775763</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>102.</dt><dd><div class="bk_ref" id="ch5.ref102">McGill
|
|
IG,
|
|
Bienenstock
|
|
J. A
|
|
comparative clinical trial of lymecycline.
|
|
British Journal of Clinical Practice.
|
|
1965;
|
|
19:462–464 [<a href="https://pubmed.ncbi.nlm.nih.gov/14324834" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14324834</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>103.</dt><dd><div class="bk_ref" id="ch5.ref103">Meyerhoff
|
|
J. Prolonged
|
|
antibiotic treatment did not relieve chronic symptoms in Lyme
|
|
disease. ACP Journal Club.
|
|
2002;
|
|
136(2):57 [<a href="https://pubmed.ncbi.nlm.nih.gov/11874282" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11874282</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>104.</dt><dd><div class="bk_ref" id="ch5.ref104">Meyerhoff
|
|
J. Long-term
|
|
antibiotics after ceftriaxone did not improve quality of life in
|
|
persistent Lyme disease. Annals of Internal
|
|
Medicine. 2016;
|
|
165(2):JC5 [<a href="https://pubmed.ncbi.nlm.nih.gov/27429317" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27429317</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>105.</dt><dd><div class="bk_ref" id="ch5.ref105">Millner
|
|
MM,
|
|
Thalhammer
|
|
GH.
|
|
Neuroborreliosis in childhood: treatment with
|
|
penicillin sodium and ceftriaxone. Acta
|
|
Dermatovenerologica Alpina, Panonica et Adriatica.
|
|
1996;
|
|
5(3–4):169–172</div></dd></dl><dl class="bkr_refwrap"><dt>106.</dt><dd><div class="bk_ref" id="ch5.ref106">Millner
|
|
MM,
|
|
Thalhammer
|
|
GH,
|
|
Dittrich
|
|
P,
|
|
Spork
|
|
KD,
|
|
Brunner
|
|
M,
|
|
Georgopoulos
|
|
A.
|
|
Beta-lactam antibiotics in the treatment of
|
|
neuroborreliosis in children: preliminary results.
|
|
Infection. 1996;
|
|
24(2):174–177 [<a href="https://pubmed.ncbi.nlm.nih.gov/8740117" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8740117</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>107.</dt><dd><div class="bk_ref" id="ch5.ref107">Morales
|
|
DS,
|
|
Siatkowski
|
|
RM,
|
|
Howard
|
|
CW,
|
|
Warman
|
|
R. Optic
|
|
neuritis in children. Journal of Pediatric
|
|
Ophthalmology and Strabismus. 2000;
|
|
37(5):254–259 [<a href="https://pubmed.ncbi.nlm.nih.gov/11020105" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11020105</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>108.</dt><dd><div class="bk_ref" id="ch5.ref108">Muellegger
|
|
R,
|
|
Zoechling
|
|
N,
|
|
Schluepen
|
|
EM,
|
|
Soyer
|
|
HP,
|
|
Hoedl
|
|
S,
|
|
Kerl
|
|
et al. Polymerase chain reaction control of antibiotic
|
|
treatment in dermatoborreliosis.
|
|
Infection. 1996;
|
|
24(1):76–79 [<a href="https://pubmed.ncbi.nlm.nih.gov/8852476" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8852476</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>109.</dt><dd><div class="bk_ref" id="ch5.ref109">Muellegger
|
|
RR,
|
|
Zoechling
|
|
N,
|
|
Soyer
|
|
HP,
|
|
Hoedl
|
|
S,
|
|
Wienecke
|
|
R,
|
|
Volkenandt
|
|
M
|
|
et al. No detection of Borrelia burgdorferi-specific
|
|
DNA in erythema migrans lesions after minocycline
|
|
treatment. Archives of Dermatology.
|
|
1995;
|
|
131(6):678–682 [<a href="https://pubmed.ncbi.nlm.nih.gov/7778919" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7778919</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>110.</dt><dd><div class="bk_ref" id="ch5.ref110">Müllegger
|
|
RR,
|
|
Millner
|
|
MM,
|
|
Stanek
|
|
G,
|
|
Spork
|
|
KD.
|
|
Penicillin G sodium and ceftriaxone in the treatment
|
|
of neuroborreliosis in children--a prospective
|
|
study. Infection. 1991;
|
|
19(4):279–283 [<a href="https://pubmed.ncbi.nlm.nih.gov/1917046" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1917046</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>111.</dt><dd><div class="bk_ref" id="ch5.ref111">Nadelman
|
|
RB,
|
|
Nowakowski
|
|
J,
|
|
Fish
|
|
D,
|
|
Falco
|
|
RC,
|
|
Freeman
|
|
K,
|
|
McKenna
|
|
D
|
|
et al. Prophylaxis with single-dose doxycycline for the
|
|
prevention of lyme disease after an Ixodes scapularis tick
|
|
bite. New England Journal of
|
|
Medicine. 2001;
|
|
345(2):79–84 [<a href="https://pubmed.ncbi.nlm.nih.gov/11450675" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11450675</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>112.</dt><dd><div class="bk_ref" id="ch5.ref112">Nadelman
|
|
RB,
|
|
Nowakowski
|
|
J,
|
|
Forseter
|
|
G,
|
|
Bittker
|
|
S,
|
|
Cooper
|
|
D,
|
|
Goldberg
|
|
N
|
|
et al. Failure to isolate Borrelia burgdorferi after
|
|
antimicrobial therapy in culture-documented Lyme borreliosis
|
|
associated with erythema migrans: report of a prospective
|
|
study. American Journal of
|
|
Medicine. 1993;
|
|
94(6):583–588 [<a href="https://pubmed.ncbi.nlm.nih.gov/8506882" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8506882</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>113.</dt><dd><div class="bk_ref" id="ch5.ref113">Naglo
|
|
AS,
|
|
Wide
|
|
K. Borrelia
|
|
infection in children. Acta Paediatrica
|
|
Scandinavica. 1989;
|
|
78(6):918–922 [<a href="https://pubmed.ncbi.nlm.nih.gov/2603720" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2603720</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>114.</dt><dd><div class="bk_ref" id="ch5.ref114">National Collaborating
|
|
Centre for Women’s and Children’s Health.
|
|
Meningitis (bacterial) and meningococcal septicaemia
|
|
in under 16s: recognition, diagnosis and management.
|
|
NICE clinical guideline 102.
|
|
London. RCOG
|
|
Press, 2010. Available from: <a href="http://guidance.nice.org.uk/CG102" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://guidance<wbr style="display:inline-block"></wbr>​.nice.org.uk/CG102</a></div></dd></dl><dl class="bkr_refwrap"><dt>115.</dt><dd><div class="bk_ref" id="ch5.ref115">National Institute for
|
|
Health and Care Excellence. Developing NICE
|
|
guidelines: the manual.
|
|
London. National
|
|
Institute for Health and Care Excellence,
|
|
2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nice.org.uk<wbr style="display:inline-block"></wbr>​/article/PMG20/chapter<wbr style="display:inline-block"></wbr>​/1%20Introduction%20and%20overview</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/26677490" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26677490</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>116.</dt><dd><div class="bk_ref" id="ch5.ref116">Neumann
|
|
R,
|
|
Aberer
|
|
E,
|
|
Stanek
|
|
G. Treatment
|
|
and course of erythema chronicum migrans.
|
|
Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene -
|
|
Series A, Medical Microbiology, Infectious Diseases, Virology,
|
|
Parasitology. 1987;
|
|
263(3):372–376 [<a href="https://pubmed.ncbi.nlm.nih.gov/3109145" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3109145</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>117.</dt><dd><div class="bk_ref" id="ch5.ref117">NHS Business Services
|
|
Authority. NHS electronic drug tariff
|
|
March
|
|
2017. Available from: <a href="http://www.drugtariff.nhsbsa.nhs.uk/#/00446515-DC_2/DC00446511/Home" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.drugtariff<wbr style="display:inline-block"></wbr>​.nhsbsa.nhs.uk/#/00446515-DC_2<wbr style="display:inline-block"></wbr>​/DC00446511/Home</a>
|
|
Last accessed: 4 April
|
|
2017.</div></dd></dl><dl class="bkr_refwrap"><dt>118.</dt><dd><div class="bk_ref" id="ch5.ref118">Nimmrich
|
|
S,
|
|
Becker
|
|
I,
|
|
Horneff
|
|
G.
|
|
Intraarticular corticosteroids in refractory
|
|
childhood Lyme arthritis. Rheumatology
|
|
International. 2014;
|
|
34(7):987–994 [<a href="https://pubmed.ncbi.nlm.nih.gov/24390634" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24390634</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>119.</dt><dd><div class="bk_ref" id="ch5.ref119">Nowakowski
|
|
J,
|
|
McKenna
|
|
D,
|
|
Nadelman
|
|
RB,
|
|
Cooper
|
|
D,
|
|
Bittker
|
|
S,
|
|
Holmgren
|
|
D
|
|
et al. Failure of treatment with cephalexin for Lyme
|
|
disease. Archives of Family
|
|
Medicine. 2000;
|
|
9(6):563–567 [<a href="https://pubmed.ncbi.nlm.nih.gov/10862221" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10862221</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>120.</dt><dd><div class="bk_ref" id="ch5.ref120">Nowakowski
|
|
J,
|
|
Nadelman
|
|
RB,
|
|
Forseter
|
|
G,
|
|
McKenna
|
|
D,
|
|
Wormser
|
|
GP.
|
|
Doxycycline versus tetracycline therapy for Lyme
|
|
disease associated with erythema migrans.
|
|
Journal of the American Academy of Dermatology.
|
|
1995; 32(2 Pt
|
|
1):223–227 [<a href="https://pubmed.ncbi.nlm.nih.gov/7829706" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7829706</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>121.</dt><dd><div class="bk_ref" id="ch5.ref121">Ogrinc
|
|
K,
|
|
Logar
|
|
M,
|
|
Lotric-Furlan
|
|
S,
|
|
Cerar
|
|
D,
|
|
Ruzic-Sabljic
|
|
E,
|
|
Strle
|
|
F.
|
|
Doxycycline versus ceftriaxone for the treatment of
|
|
patients with chronic Lyme borreliosis.
|
|
Wiener Klinische Wochenschrift. 2006;
|
|
118(21):696–701 [<a href="https://pubmed.ncbi.nlm.nih.gov/17160610" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17160610</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>122.</dt><dd><div class="bk_ref" id="ch5.ref122">Oksi
|
|
J,
|
|
Marjamaki
|
|
M,
|
|
Nikoskelainen
|
|
J,
|
|
Viljanen
|
|
MK. Borrelia
|
|
burgdorferi detected by culture and PCR in clinical relapse of
|
|
disseminated Lyme borreliosis. Annals of
|
|
Medicine. 1999;
|
|
31(3):225–232 [<a href="https://pubmed.ncbi.nlm.nih.gov/10442678" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10442678</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>123.</dt><dd><div class="bk_ref" id="ch5.ref123">Oksi
|
|
J,
|
|
Nikoskelainen
|
|
J,
|
|
Hiekkanen
|
|
H,
|
|
Lauhio
|
|
A,
|
|
Peltomaa
|
|
M,
|
|
Pitkäranta
|
|
A
|
|
et al. Duration of antibiotic treatment in disseminated
|
|
Lyme borreliosis: a double-blind, randomized, placebo-controlled,
|
|
multicenter clinical study. European Journal
|
|
of Clinical Microbiology and Infectious Diseases.
|
|
2007;
|
|
26(8):571–581 [<a href="https://pubmed.ncbi.nlm.nih.gov/17587070" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17587070</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>124.</dt><dd><div class="bk_ref" id="ch5.ref124">Oksi
|
|
J,
|
|
Nikoskelainen
|
|
J,
|
|
Viljanen
|
|
MK.
|
|
Comparison of oral cefixime and intravenous
|
|
ceftriaxone followed by oral amoxicillin in disseminated Lyme
|
|
borreliosis. European Journal of Clinical
|
|
Microbiology and Infectious Diseases. 1998;
|
|
17(10):715–719 [<a href="https://pubmed.ncbi.nlm.nih.gov/9865985" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9865985</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>125.</dt><dd><div class="bk_ref" id="ch5.ref125">Peltomaa
|
|
M,
|
|
Saxen
|
|
H,
|
|
Seppala
|
|
I,
|
|
Viljanen
|
|
M,
|
|
Pyykko
|
|
I.
|
|
Paediatric facial paralysis caused by Lyme
|
|
borreliosis: a prospective and retrospective
|
|
analysis. Scandinavian Journal of Infectious
|
|
Diseases. 1998;
|
|
30(3):269–275 [<a href="https://pubmed.ncbi.nlm.nih.gov/9790136" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9790136</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>126.</dt><dd><div class="bk_ref" id="ch5.ref126">Pena
|
|
CA,
|
|
Mathews
|
|
AA,
|
|
Siddiqi
|
|
NH,
|
|
Strickland
|
|
GT.
|
|
Antibiotic therapy for lyme disease in a
|
|
population-based cohort. Clinical Infectious
|
|
Diseases. 1999;
|
|
29(3):694–695 [<a href="https://pubmed.ncbi.nlm.nih.gov/10530478" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10530478</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>127.</dt><dd><div class="bk_ref" id="ch5.ref127">Perronne
|
|
C. Critical
|
|
review of studies trying to evaluate the treatment of chronic Lyme
|
|
disease. Presse Medicale.
|
|
2015;
|
|
44(7–8):828–831 [<a href="https://pubmed.ncbi.nlm.nih.gov/26206701" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26206701</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>128.</dt><dd><div class="bk_ref" id="ch5.ref128">Pfister
|
|
HW,
|
|
Einhaupl
|
|
KM,
|
|
Franz
|
|
P,
|
|
Garner
|
|
C.
|
|
Corticosteroids for radicular pain in
|
|
Bannwarth’s syndrome: a double-blind, randomized,
|
|
placebo-controlled trial. Annals of the New
|
|
York Academy of Sciences. 1988;
|
|
539(1):485–487</div></dd></dl><dl class="bkr_refwrap"><dt>129.</dt><dd><div class="bk_ref" id="ch5.ref129">Pfister
|
|
HW,
|
|
Preac-Mursic
|
|
V,
|
|
Wilske
|
|
B,
|
|
Einhäupl
|
|
KM.
|
|
Cefotaxime vs penicillin G for acute neurologic
|
|
manifestations in Lyme borreliosis. A prospective randomized
|
|
study. Archives of Neurology.
|
|
1989;
|
|
46(11):1190–1194 [<a href="https://pubmed.ncbi.nlm.nih.gov/2684107" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2684107</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>130.</dt><dd><div class="bk_ref" id="ch5.ref130">Pfister
|
|
HW,
|
|
Preac-Mursic
|
|
V,
|
|
Wilske
|
|
B,
|
|
Schielke
|
|
E,
|
|
Sorgel
|
|
F,
|
|
Einhaupl
|
|
KM.
|
|
Randomized comparison of ceftriaxone and cefotaxime
|
|
in Lyme neuroborreliosis. Journal of
|
|
Infectious Diseases. 1991;
|
|
163(2):311–318 [<a href="https://pubmed.ncbi.nlm.nih.gov/1988514" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1988514</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>131.</dt><dd><div class="bk_ref" id="ch5.ref131">Pirila
|
|
V. The
|
|
penicillin treatment of acrodermatitis atrophicans
|
|
chronica. Acta
|
|
Dermato-Venereologica. 1951;
|
|
31(5):576–591 [<a href="https://pubmed.ncbi.nlm.nih.gov/14914395" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14914395</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>132.</dt><dd><div class="bk_ref" id="ch5.ref132">Plorer
|
|
A,
|
|
Sepp
|
|
N,
|
|
Schmutzhard
|
|
E,
|
|
Krabichler
|
|
S,
|
|
Trobos
|
|
S,
|
|
Schauer
|
|
G
|
|
et al. Effects of adequate versus inadequate treatment
|
|
of cutaneous manifestations of Lyme borreliosis on the incidence of
|
|
late complications and late serologic status.
|
|
Journal of Investigative Dermatology.
|
|
1993;
|
|
100(2):103–109 [<a href="https://pubmed.ncbi.nlm.nih.gov/8429231" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8429231</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>133.</dt><dd><div class="bk_ref" id="ch5.ref133">Plotkin
|
|
SA,
|
|
Peter
|
|
G. Treatment
|
|
of Lyme borreliosis. Pediatrics.
|
|
1991;
|
|
88(1):176–179 [<a href="https://pubmed.ncbi.nlm.nih.gov/2057259" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2057259</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>134.</dt><dd><div class="bk_ref" id="ch5.ref134">Puchalska
|
|
B,
|
|
Niemcunowicz-Janica
|
|
A,
|
|
Kondej Muszynska
|
|
K,
|
|
Trippner
|
|
M. Lyme
|
|
borreliosis--tick borne spirochaetosis among
|
|
children. Roczniki Akademii Medycznej w
|
|
Bialymstoku (1995). 1996;
|
|
41(1):59–61 [<a href="https://pubmed.ncbi.nlm.nih.gov/8673806" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8673806</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>135.</dt><dd><div class="bk_ref" id="ch5.ref135">Puri
|
|
BK,
|
|
Hakkarainen-Smith
|
|
JS,
|
|
Derham
|
|
A,
|
|
Monro
|
|
JA.
|
|
Co-administration of alpha-lipoic acid and
|
|
glutathione is associated with no significant changes in serum
|
|
bilirubin, alkaline phosphatase or gamma-glutamyltranspeptidase
|
|
levels during the treatment of neuroborreliosis with intravenous
|
|
ceftriaxone. Journal of Complementary and
|
|
Integrative Medicine. 2015;
|
|
12(3):227–230 [<a href="https://pubmed.ncbi.nlm.nih.gov/25968441" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25968441</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>136.</dt><dd><div class="bk_ref" id="ch5.ref136">Puri
|
|
BK,
|
|
Hakkarainen-Smith
|
|
JS,
|
|
Monro
|
|
JA. The
|
|
potential use of cholestyramine to reduce the risk of developing
|
|
Clostridium difficile-associated diarrhoea in patients receiving
|
|
long-term intravenous ceftriaxone. Medical
|
|
Hypotheses. 2015;
|
|
84(1):78–80 [<a href="https://pubmed.ncbi.nlm.nih.gov/25497389" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25497389</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>137.</dt><dd><div class="bk_ref" id="ch5.ref137">Rebman
|
|
AW,
|
|
Crowder
|
|
LA,
|
|
Kirkpatrick
|
|
A,
|
|
Aucott
|
|
JN.
|
|
Characteristics of seroconversion and implications
|
|
for diagnosis of post-treatment Lyme disease syndrome: acute and
|
|
convalescent serology among a prospective cohort of early Lyme
|
|
disease patients. Clinical
|
|
Rheumatology. 2015;
|
|
34(3):585–589 [<a href="https://pubmed.ncbi.nlm.nih.gov/24924604" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24924604</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>138.</dt><dd><div class="bk_ref" id="ch5.ref138">Renaud
|
|
I,
|
|
Cachin
|
|
C,
|
|
Gerster
|
|
JC. Good
|
|
outcomes of Lyme arthritis in 24 patients in an endemic area of
|
|
Switzerland. Joint, Bone, Spine: Revue du
|
|
Rhumatisme. 2004;
|
|
71(1):39–43 [<a href="https://pubmed.ncbi.nlm.nih.gov/14769519" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14769519</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>139.</dt><dd><div class="bk_ref" id="ch5.ref139">Rohacova
|
|
H,
|
|
Hancil
|
|
J,
|
|
Hulinska
|
|
D,
|
|
Mailer
|
|
H,
|
|
Havlik
|
|
J.
|
|
Ceftriaxone in the treatment of Lyme
|
|
neuroborreliosis. Infection.
|
|
1996;
|
|
24(1):88–90 [<a href="https://pubmed.ncbi.nlm.nih.gov/8852479" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8852479</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>140.</dt><dd><div class="bk_ref" id="ch5.ref140">Rose
|
|
CD,
|
|
Fawcett
|
|
PT,
|
|
Eppes
|
|
SC,
|
|
Klein
|
|
JD,
|
|
Gibney
|
|
K,
|
|
Doughty
|
|
RA.
|
|
Pediatric Lyme arthritis: clinical spectrum and
|
|
outcome. Journal of Pediatric
|
|
Orthopaedics. 1994;
|
|
14(2):238–241 [<a href="https://pubmed.ncbi.nlm.nih.gov/8188841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8188841</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>141.</dt><dd><div class="bk_ref" id="ch5.ref141">Rose
|
|
CD,
|
|
Fawcett
|
|
PT,
|
|
Gibney
|
|
KM,
|
|
Doughty
|
|
RA. Residual
|
|
serologic reactivity in children with resolved Lyme
|
|
arthritis. Journal of Rheumatology.
|
|
1996;
|
|
23(2):367–369 [<a href="https://pubmed.ncbi.nlm.nih.gov/8882048" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8882048</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>142.</dt><dd><div class="bk_ref" id="ch5.ref142">Rubin
|
|
DA,
|
|
Sorbera
|
|
C,
|
|
Nikitin
|
|
P,
|
|
McAllister
|
|
A,
|
|
Wormser
|
|
GP,
|
|
Nadelman
|
|
RB.
|
|
Prospective evaluation of heart block complicating
|
|
early Lyme disease. PACE - Pacing and
|
|
Clinical Electrophysiology. 1992;
|
|
15(3):252–255 [<a href="https://pubmed.ncbi.nlm.nih.gov/1372717" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1372717</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>143.</dt><dd><div class="bk_ref" id="ch5.ref143">Salazar
|
|
CA,
|
|
Rothemich
|
|
M,
|
|
Drouin
|
|
EE,
|
|
Glickstein
|
|
L,
|
|
Steere
|
|
AC. Human
|
|
Lyme arthritis and the immunoglobulin G antibody response to the
|
|
37-kilodalton arthritis-related protein of Borrelia
|
|
burgdorferi. Infection and
|
|
Immunity. 2005;
|
|
73(5):2951–2957 [<a href="/pmc/articles/PMC1087337/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1087337</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15845501" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15845501</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>144.</dt><dd><div class="bk_ref" id="ch5.ref144">Salazar
|
|
JC,
|
|
Gerber
|
|
MA,
|
|
Goff
|
|
CW.
|
|
Long-term outcome of Lyme disease in children given
|
|
early treatment. Journal of
|
|
Pediatrics. 1993;
|
|
122(4):591–593 [<a href="https://pubmed.ncbi.nlm.nih.gov/8463906" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8463906</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>145.</dt><dd><div class="bk_ref" id="ch5.ref145">Sanchez
|
|
E,
|
|
Vannier
|
|
E,
|
|
Wormser
|
|
GP,
|
|
Hu
|
|
LT.
|
|
Diagnosis, treatment, and prevention of Lyme disease,
|
|
human granulocytic anaplasmosis, and babesiosis: a
|
|
review. JAMA. 2016;
|
|
315(16):1767–1777 [<a href="/pmc/articles/PMC7758915/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7758915</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27115378" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27115378</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>146.</dt><dd><div class="bk_ref" id="ch5.ref146">Sandstrom
|
|
M,
|
|
Bredberg
|
|
G,
|
|
Asbrink
|
|
E,
|
|
Hovmark
|
|
A,
|
|
Holmkvist
|
|
C. Brainstem
|
|
response audiometry in chronic Lyme borreliosis.
|
|
Scandinavian Audiology. 1989;
|
|
18(4):205–210 [<a href="https://pubmed.ncbi.nlm.nih.gov/2609097" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2609097</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>147.</dt><dd><div class="bk_ref" id="ch5.ref147">Schmidt
|
|
BL,
|
|
Aberer
|
|
E,
|
|
Stockenhuber
|
|
C,
|
|
Klade
|
|
H,
|
|
Breier
|
|
F,
|
|
Luger
|
|
A. Detection
|
|
of Borrelia burgdorferi DNA by polymerase chain reaction in the
|
|
urine and breast milk of patients with Lyme
|
|
borreliosis. Diagnostic Microbiology and
|
|
Infectious Disease. 1995;
|
|
21(3):121–128 [<a href="https://pubmed.ncbi.nlm.nih.gov/7648832" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7648832</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>148.</dt><dd><div class="bk_ref" id="ch5.ref148">Selby
|
|
G,
|
|
Bridges
|
|
SJ,
|
|
Hanington
|
|
L. Should
|
|
Lyme disease affecting the nervous system be treated with oral or
|
|
intravenous antibiotics?
|
|
Archives of Disease in Childhood Education &
|
|
Practice. 2008;
|
|
93(4):132–134 [<a href="https://pubmed.ncbi.nlm.nih.gov/18644904" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18644904</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>149.</dt><dd><div class="bk_ref" id="ch5.ref149">Shadick
|
|
NA,
|
|
Phillips
|
|
CB,
|
|
Logigian
|
|
EL,
|
|
Steere
|
|
AC,
|
|
Kaplan
|
|
RF,
|
|
Berardi
|
|
VP
|
|
et al. The long-term clinical outcomes of Lyme disease.
|
|
A population-based retrospective cohort study.
|
|
Annals of Internal Medicine. 1994;
|
|
121(8):560–567 [<a href="https://pubmed.ncbi.nlm.nih.gov/8085687" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8085687</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>150.</dt><dd><div class="bk_ref" id="ch5.ref150">Shadick
|
|
NA,
|
|
Phillips
|
|
CB,
|
|
Sangha
|
|
O,
|
|
Logigian
|
|
EL,
|
|
Kaplan
|
|
RF,
|
|
Wright
|
|
EA
|
|
et al. Musculoskeletal and neurologic outcomes in
|
|
patients with previously treated lyme disease.
|
|
Annals of Internal Medicine. 1999;
|
|
131(12):919–926 [<a href="https://pubmed.ncbi.nlm.nih.gov/10610642" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10610642</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>151.</dt><dd><div class="bk_ref" id="ch5.ref151">Shemenski
|
|
J.
|
|
Cimetidine as a novel adjunctive treatment for early
|
|
stage Lyme disease. Medical
|
|
Hypotheses. 2016;
|
|
Epublication [<a href="https://pubmed.ncbi.nlm.nih.gov/27107653" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27107653</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>152.</dt><dd><div class="bk_ref" id="ch5.ref152">Shoemaker
|
|
RC,
|
|
Hudnell
|
|
HK,
|
|
House
|
|
DE,
|
|
Kempen
|
|
A,
|
|
Pakes
|
|
GE.
|
|
Atovaquone plus cholestyramine in patients coinfected
|
|
with Babesia microti and Borrelia burgdorferi refractory to other
|
|
treatment. Advances in Therapy.
|
|
2006;
|
|
23(1):1–11 [<a href="https://pubmed.ncbi.nlm.nih.gov/16644602" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16644602</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>153.</dt><dd><div class="bk_ref" id="ch5.ref153">Sjowall
|
|
J,
|
|
Fryland
|
|
L,
|
|
Nordberg
|
|
M,
|
|
Sjogren
|
|
F,
|
|
Garpmo
|
|
U,
|
|
Jansson
|
|
C
|
|
et al. Decreased Th1-type inflammatory cytokine
|
|
expression in the skin is associated with persisting symptoms after
|
|
treatment of erythema migrans. PloS
|
|
One. 2011;
|
|
6(3):e18220 [<a href="/pmc/articles/PMC3069060/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3069060</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21483819" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21483819</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>154.</dt><dd><div class="bk_ref" id="ch5.ref154">Sjöwall
|
|
J,
|
|
Ledel
|
|
A,
|
|
Ernerudh
|
|
J,
|
|
Ekerfelt
|
|
C,
|
|
Forsberg
|
|
P.
|
|
Doxycycline-mediated effects on persistent symptoms
|
|
and systemic cytokine responses post-neuroborreliosis: a randomized,
|
|
prospective, cross-over study. BMC
|
|
Infectious Diseases. 2012;
|
|
12:186 [<a href="/pmc/articles/PMC3507907/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3507907</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22876748" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22876748</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>155.</dt><dd><div class="bk_ref" id="ch5.ref155">Skogman
|
|
BH,
|
|
Croner
|
|
S,
|
|
Nordwall
|
|
M,
|
|
Eknefelt
|
|
M,
|
|
Ernerudh
|
|
J,
|
|
Forsberg
|
|
P. Lyme
|
|
neuroborreliosis in children: a prospective study of clinical
|
|
features, prognosis, and outcome. Pediatric
|
|
Infectious Disease Journal. 2008;
|
|
27(12):1089–1094 [<a href="https://pubmed.ncbi.nlm.nih.gov/19008771" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19008771</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>156.</dt><dd><div class="bk_ref" id="ch5.ref156">Skogman
|
|
BH,
|
|
Croner
|
|
S,
|
|
Odkvist
|
|
L. Acute
|
|
facial palsy in children - a 2-year follow-up study with focus on
|
|
Lyme neuroborreliosis. International Journal
|
|
of Pediatric Otorhinolaryngology. 2003;
|
|
67(6):597–602 [<a href="https://pubmed.ncbi.nlm.nih.gov/12745151" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12745151</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>157.</dt><dd><div class="bk_ref" id="ch5.ref157">Skoldenberg
|
|
B,
|
|
Stiernstedt
|
|
G,
|
|
Karlsson
|
|
M,
|
|
Wretlind
|
|
B,
|
|
Svenungsson
|
|
B. Treatment
|
|
of Lyme borreliosis with emphasis on neurological
|
|
disease. Annals of the New York Academy of
|
|
Sciences. 1988;
|
|
539:317–323 [<a href="https://pubmed.ncbi.nlm.nih.gov/3056201" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3056201</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>158.</dt><dd><div class="bk_ref" id="ch5.ref158">Smith
|
|
RP,
|
|
Schoen
|
|
RT,
|
|
Rahn
|
|
DW,
|
|
Sikand
|
|
VK,
|
|
Nowakowski
|
|
J,
|
|
Parenti
|
|
DL
|
|
et al. Clinical characteristics and treatment outcome
|
|
of early Lyme disease in patients with microbiologically confirmed
|
|
erythema migrans. Annals of Internal
|
|
Medicine. 2002;
|
|
136(6):421–428 [<a href="https://pubmed.ncbi.nlm.nih.gov/11900494" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11900494</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>159.</dt><dd><div class="bk_ref" id="ch5.ref159">Solomon
|
|
SP,
|
|
Hilton
|
|
E,
|
|
Weinschel
|
|
BS,
|
|
Pollack
|
|
S,
|
|
Grolnick
|
|
E.
|
|
Psychological factors in the prediction of Lyme
|
|
disease course. Arthritis Care and
|
|
Research. 1998;
|
|
11(5):419–426 [<a href="https://pubmed.ncbi.nlm.nih.gov/9830887" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9830887</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>160.</dt><dd><div class="bk_ref" id="ch5.ref160">Spathling
|
|
S,
|
|
J
|
|
dK,
|
|
P
|
|
H. Therapy
|
|
of Lyme arthritis with ceftriaxon - histological proof of
|
|
spriochates in the synovialis after ineffective
|
|
therapy. Zeitschrift für
|
|
Rheumatologie. 1992;
|
|
51:(Suppl
|
|
2):40–41</div></dd></dl><dl class="bkr_refwrap"><dt>161.</dt><dd><div class="bk_ref" id="ch5.ref161">Stanek
|
|
G,
|
|
Breier
|
|
F,
|
|
Menzinger
|
|
G,
|
|
Schaar
|
|
B,
|
|
Hafner
|
|
M,
|
|
Partsch
|
|
H. Erythema
|
|
migrans and serodiagnosis by enzyme immunoassay and immunoblot with
|
|
three borrelia species. Wiener Klinische
|
|
Wochenschrift. 1999;
|
|
111(22–23):951–956 [<a href="https://pubmed.ncbi.nlm.nih.gov/10666807" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10666807</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>162.</dt><dd><div class="bk_ref" id="ch5.ref162">Steere
|
|
AC,
|
|
Green
|
|
J,
|
|
Hutchinson
|
|
GJ,
|
|
Rahn
|
|
DW,
|
|
Pachner
|
|
AR,
|
|
Schoen
|
|
RT
|
|
et al. Treatment of Lyme disease.
|
|
Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene -
|
|
Series A, Medical Microbiology, Infectious Diseases, Virology,
|
|
Parasitology. 1987;
|
|
263(3):352–356 [<a href="https://pubmed.ncbi.nlm.nih.gov/3109144" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3109144</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>163.</dt><dd><div class="bk_ref" id="ch5.ref163">Steere
|
|
AC,
|
|
Green
|
|
J,
|
|
Schoen
|
|
RT,
|
|
Taylor
|
|
E,
|
|
Hutchinson
|
|
GJ,
|
|
Rahn
|
|
DW
|
|
et al. Successful parenteral penicillin therapy of
|
|
established Lyme arthritis. New England
|
|
Journal of Medicine. 1985;
|
|
312(14):869–874 [<a href="https://pubmed.ncbi.nlm.nih.gov/3883177" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3883177</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>164.</dt><dd><div class="bk_ref" id="ch5.ref164">Steere
|
|
AC,
|
|
Hutchinson
|
|
GJ,
|
|
Rahn
|
|
DW,
|
|
Sigal
|
|
LH,
|
|
Craft
|
|
JE,
|
|
DeSanna
|
|
ET
|
|
et al. Treatment of the early manifestations of Lyme
|
|
disease. Annals of Internal
|
|
Medicine. 1983;
|
|
99(1):22–26 [<a href="https://pubmed.ncbi.nlm.nih.gov/6407378" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6407378</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>165.</dt><dd><div class="bk_ref" id="ch5.ref165">Steere
|
|
AC,
|
|
Malawista
|
|
SE,
|
|
Newman
|
|
JH,
|
|
Spieler
|
|
PN,
|
|
Bartenhagen
|
|
NH.
|
|
Antibiotic therapy in Lyme disease.
|
|
Annals of Internal Medicine. 1980;
|
|
93(1
|
|
I):1–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/6967272" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6967272</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>166.</dt><dd><div class="bk_ref" id="ch5.ref166">Steere
|
|
AC,
|
|
Pachner
|
|
AR,
|
|
Malawista
|
|
SE.
|
|
Neurologic abnormalities of Lyme disease: successful
|
|
treatment with high-dose intravenous penicillin.
|
|
Annals of Internal Medicine. 1983;
|
|
99(6):767–772 [<a href="https://pubmed.ncbi.nlm.nih.gov/6316826" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6316826</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>167.</dt><dd><div class="bk_ref" id="ch5.ref167">Steurer
|
|
J.
|
|
Month-long antibiotic therapy has no effect in
|
|
persistent symptoms of Lyme disease.
|
|
Praxis. 2016;
|
|
105(12):723–724 [<a href="https://pubmed.ncbi.nlm.nih.gov/27269781" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27269781</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>168.</dt><dd><div class="bk_ref" id="ch5.ref168">Stricker
|
|
RB,
|
|
Delong
|
|
AK,
|
|
Green
|
|
CL,
|
|
Savely
|
|
VR,
|
|
Chamallas
|
|
SN,
|
|
Johnson
|
|
L. Benefit
|
|
of intravenous antibiotic therapy in patients referred for treatment
|
|
of neurologic Lyme disease. International
|
|
Journal of General Medicine. 2011;
|
|
4:639–646 [<a href="/pmc/articles/PMC3177589/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3177589</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21941449" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21941449</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>169.</dt><dd><div class="bk_ref" id="ch5.ref169">Stricker
|
|
RB,
|
|
Green
|
|
CL,
|
|
Savely
|
|
VR,
|
|
Chamallas
|
|
SN,
|
|
Johnson
|
|
L. Safety of
|
|
intravenous antibiotic therapy in patients referred for treatment of
|
|
neurologic Lyme disease. Minerva
|
|
Medica. 2010;
|
|
101(1):1–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/20228716" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20228716</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>170.</dt><dd><div class="bk_ref" id="ch5.ref170">Strle
|
|
F,
|
|
Maraspin
|
|
V,
|
|
Lotric-Furlan
|
|
S,
|
|
Ruzic-Sabljic
|
|
E,
|
|
Cimperman
|
|
J.
|
|
Azithromycin and doxycycline for treatment of
|
|
borrelia culture-positive erythema migrans.
|
|
Infection. 1996;
|
|
24(1):64–68 [<a href="https://pubmed.ncbi.nlm.nih.gov/8852473" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8852473</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>171.</dt><dd><div class="bk_ref" id="ch5.ref171">Strle
|
|
F,
|
|
Maraspin
|
|
V,
|
|
Pleterski-Rigler
|
|
D,
|
|
Lotric-Furlan
|
|
S,
|
|
Ruzic-Sabljic
|
|
E,
|
|
Jurca
|
|
T
|
|
et al. Treatment of borrelial
|
|
lymphocytoma. Infection.
|
|
1996;
|
|
24(1):80–84 [<a href="https://pubmed.ncbi.nlm.nih.gov/8852477" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8852477</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>172.</dt><dd><div class="bk_ref" id="ch5.ref172">Strle
|
|
F,
|
|
Pleterski-Rigler
|
|
D,
|
|
Stanek
|
|
G,
|
|
Pejovnik-Pustinek
|
|
A,
|
|
Ruzic
|
|
E,
|
|
Cimperman
|
|
J. Solitary
|
|
borrelial lymphocytoma: report of 36 cases.
|
|
Infection. 1992;
|
|
20(4):201–206 [<a href="https://pubmed.ncbi.nlm.nih.gov/1521885" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1521885</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>173.</dt><dd><div class="bk_ref" id="ch5.ref173">Strle
|
|
F,
|
|
Preac-Mursic
|
|
V,
|
|
Cimperman
|
|
J,
|
|
Ruzic
|
|
E,
|
|
Maraspin
|
|
V,
|
|
Jereb
|
|
M.
|
|
Azithromycin versus doxycycline for treatment of
|
|
erythema migrans: clinical and microbiological
|
|
findings. Infection.
|
|
1993;
|
|
21(2):83–88 [<a href="https://pubmed.ncbi.nlm.nih.gov/8387966" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8387966</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>174.</dt><dd><div class="bk_ref" id="ch5.ref174">Stupica
|
|
D,
|
|
Lusa
|
|
L,
|
|
Cerar
|
|
T,
|
|
Ruzic-Sabljic
|
|
E,
|
|
Strle
|
|
F.
|
|
Comparison of post-lyme borreliosis symptoms in
|
|
erythema migrans patients with positive and negative borrelia
|
|
burgdorferi sensu lato skin culture.
|
|
Vector-Borne and Zoonotic Diseases.
|
|
2011;
|
|
11(7):883–889 [<a href="https://pubmed.ncbi.nlm.nih.gov/21083376" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21083376</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>175.</dt><dd><div class="bk_ref" id="ch5.ref175">Stupica
|
|
D,
|
|
Lusa
|
|
L,
|
|
Maraspin
|
|
V,
|
|
Bogovic
|
|
P,
|
|
Vidmar
|
|
D,
|
|
O’Rourke
|
|
M
|
|
et al. Correlation of culture positivity, PCR
|
|
positivity, and burden of Borrelia burgdorferi sensu lato in skin
|
|
samples of erythema migrans patients with clinical
|
|
findings. PloS One.
|
|
2015;
|
|
10(9):e0136600 [<a href="/pmc/articles/PMC4564201/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4564201</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26352832" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26352832</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>176.</dt><dd><div class="bk_ref" id="ch5.ref176">Suarez-Magdalena
|
|
O,
|
|
Fernandez-Jorge
|
|
B,
|
|
Campo-Cerecedo
|
|
F,
|
|
Varela-Veiga
|
|
A.
|
|
Atrophoderma of Pasini and Pierini associated with
|
|
Borrelia burgdorferi treated with doxycycline.
|
|
Piel. 2017;
|
|
32(2):120–122</div></dd></dl><dl class="bkr_refwrap"><dt>177.</dt><dd><div class="bk_ref" id="ch5.ref177">Thompson
|
|
AD,
|
|
Cohn
|
|
KA,
|
|
Shah
|
|
SS,
|
|
Lyons
|
|
T,
|
|
Welsh
|
|
EJ,
|
|
Hines
|
|
EM
|
|
et al. Treatment complications in children with Lyme
|
|
meningitis. Pediatric Infectious Disease
|
|
Journal. 2012;
|
|
31(10):1032–1035 [<a href="https://pubmed.ncbi.nlm.nih.gov/22592517" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22592517</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>178.</dt><dd><div class="bk_ref" id="ch5.ref178">Thorstrand
|
|
C,
|
|
Belfrage
|
|
E,
|
|
Bennet
|
|
R,
|
|
Malmborg
|
|
P,
|
|
Eriksson
|
|
M.
|
|
Successful treatment of neuroborreliosis with ten day
|
|
regimens. Pediatric Infectious Disease
|
|
Journal. 2002;
|
|
21(12):1142–1145 [<a href="https://pubmed.ncbi.nlm.nih.gov/12488665" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12488665</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>179.</dt><dd><div class="bk_ref" id="ch5.ref179">Thyresson
|
|
N. The
|
|
penicillin treatment of acrodermatitis atrophicans chronica
|
|
(Herxheimer). Acta
|
|
Dermato-Venereologica. 1949;
|
|
29(6):572–621 [<a href="https://pubmed.ncbi.nlm.nih.gov/18140373" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18140373</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>180.</dt><dd><div class="bk_ref" id="ch5.ref180">Torbahn
|
|
G,
|
|
Hofmann
|
|
H,
|
|
Allert
|
|
R,
|
|
Freitag
|
|
MH,
|
|
Dersch
|
|
R,
|
|
Fingerle
|
|
V
|
|
et al. Efficacy and safety of pharmacological agents in
|
|
the treatment of erythema migrans in early Lyme
|
|
borreliosis-systematic review protocol.
|
|
Systems Review. 2016;
|
|
5:73 [<a href="/pmc/articles/PMC4855495/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4855495</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27142846" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27142846</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>181.</dt><dd><div class="bk_ref" id="ch5.ref181">Tory
|
|
HO,
|
|
Zurakowski
|
|
D,
|
|
Sundel
|
|
RP. Outcomes
|
|
of children treated for Lyme arthritis: results of a large pediatric
|
|
cohort. Journal of Rheumatology.
|
|
2010;
|
|
37(5):1049–1055 [<a href="https://pubmed.ncbi.nlm.nih.gov/20360182" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20360182</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>182.</dt><dd><div class="bk_ref" id="ch5.ref182">Tseng
|
|
YJ,
|
|
Demaria
|
|
A,
|
|
Goldmann
|
|
DA,
|
|
Mandl
|
|
KD.
|
|
Claims-based diagnostic patterns of patients
|
|
evaluated for lyme disease and given extended antibiotic
|
|
therapy. Vector-Borne and Zoonotic
|
|
Diseases. 2017;
|
|
17(2):116–122 [<a href="https://pubmed.ncbi.nlm.nih.gov/27855040" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27855040</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>183.</dt><dd><div class="bk_ref" id="ch5.ref183">Valesova
|
|
H,
|
|
Mailer
|
|
J,
|
|
Havlik
|
|
J,
|
|
Hulinska
|
|
D,
|
|
Hercogova
|
|
J. Long-term
|
|
results in patients with Lyme arthritis following treatment with
|
|
ceftriaxone. Infection.
|
|
1996;
|
|
24(1):98–102 [<a href="https://pubmed.ncbi.nlm.nih.gov/8852482" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8852482</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>184.</dt><dd><div class="bk_ref" id="ch5.ref184">Vazquez-Lopez
|
|
ME,
|
|
Diez-Morrondo
|
|
C,
|
|
Sanchez-Andrade
|
|
A,
|
|
Pego-Reigosa
|
|
R,
|
|
Diaz
|
|
P,
|
|
Castro-Gago
|
|
M. Articular
|
|
manifestations in patients with Lyme disease.
|
|
Reumatologia Clinica. 2016;
|
|
12(6):327–330 [<a href="https://pubmed.ncbi.nlm.nih.gov/26706656" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26706656</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>185.</dt><dd><div class="bk_ref" id="ch5.ref185">Vazquez
|
|
M,
|
|
Sparrow
|
|
SS,
|
|
Shapiro
|
|
ED.
|
|
Long-term neuropsychologic and health outcomes of
|
|
children with facial nerve palsy attributable to Lyme
|
|
disease. Pediatrics.
|
|
2003;
|
|
112(2):e93–97 [<a href="https://pubmed.ncbi.nlm.nih.gov/12897313" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12897313</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>186.</dt><dd><div class="bk_ref" id="ch5.ref186">Wahlberg
|
|
P,
|
|
Granlund
|
|
H,
|
|
Nyman
|
|
D,
|
|
Panelius
|
|
J,
|
|
Seppala
|
|
I. Treatment
|
|
of late Lyme borreliosis. Journal of
|
|
Infection. 1994;
|
|
29(3):255–261 [<a href="https://pubmed.ncbi.nlm.nih.gov/7884218" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7884218</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>187.</dt><dd><div class="bk_ref" id="ch5.ref187">Weber
|
|
K,
|
|
Neubert
|
|
U,
|
|
Thurmayr
|
|
R.
|
|
Antibiotic therapy in early erythema migrans disease
|
|
and related disorders. Zentralblatt fur
|
|
Bakteriologie, Mikrobiologie, und Hygiene - Series A, Medical
|
|
Microbiology, Infectious Diseases, Virology, Parasitology.
|
|
1987;
|
|
263(3):377–388 [<a href="https://pubmed.ncbi.nlm.nih.gov/3591091" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3591091</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>188.</dt><dd><div class="bk_ref" id="ch5.ref188">Weber
|
|
K,
|
|
Preac-Mursic
|
|
V,
|
|
Neubert
|
|
U,
|
|
Thurmayr
|
|
R,
|
|
Herzer
|
|
P,
|
|
Wilske
|
|
B
|
|
et al. Antibiotic therapy of early European Lyme
|
|
borreliosis and acrodermatitis chronica atrophicans.
|
|
Annals of the New York Academy of Sciences.
|
|
1988;
|
|
539:324–345 [<a href="https://pubmed.ncbi.nlm.nih.gov/3056202" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3056202</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>189.</dt><dd><div class="bk_ref" id="ch5.ref189">Weissenbacher
|
|
S,
|
|
Ring
|
|
J,
|
|
Hofmann
|
|
H.
|
|
Gabapentin for the symptomatic treatment of chronic
|
|
neuropathic pain in patients with late-stage lyme borreliosis: a
|
|
pilot study. Dermatology.
|
|
2005;
|
|
211(2):123–127 [<a href="https://pubmed.ncbi.nlm.nih.gov/16088158" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16088158</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>190.</dt><dd><div class="bk_ref" id="ch5.ref190">White
|
|
B,
|
|
Seaton
|
|
RA,
|
|
Evans
|
|
TJ.
|
|
Management of suspected lyme borreliosis: experience
|
|
from an outpatient parenteral antibiotic therapy
|
|
service. QJM. 2013;
|
|
106(2):133–138 [<a href="https://pubmed.ncbi.nlm.nih.gov/23070203" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23070203</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>191.</dt><dd><div class="bk_ref" id="ch5.ref191">Zochling
|
|
N,
|
|
Mullegger
|
|
RR,
|
|
Schluepen
|
|
EM,
|
|
Soyer
|
|
HP,
|
|
Hodl
|
|
S,
|
|
Wienecke
|
|
R
|
|
et al. Minocycline in early Lyme
|
|
Borreliosis. Acta Dermatovenerologica
|
|
Alpina, Panonica et Adriatica. 1996;
|
|
5(3–4):163–168</div></dd></dl></dl></div><div id="appendixesappgroup5"><h2 id="_appendixesappgroup5_">Appendices</h2><div id="ch5.appa"><h3>Appendix A. Review protocols</h3><p id="ch5.appa.tab1"><a href="/books/NBK578166/table/ch5.appa.tab1/?report=objectonly" target="object" rid-ob="figobch5appatab1" class="figpopup">Table 4. Review protocol for the management of non-specific
|
|
symptoms</a></p><p id="ch5.appa.tab2"><a href="/books/NBK578166/table/ch5.appa.tab2/?report=objectonly" target="object" rid-ob="figobch5appatab2" class="figpopup">Table 5. Health economic review protocol</a></p></div><div id="ch5.appb"><h3>Appendix B. Literature search strategies</h3><p>The literature searches for this review are detailed below and complied
|
|
with the methodology outlined in Developing NICE guidelines: the manual
|
|
2014, updated 2017</p><p>
|
|
<a href="https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869</a>
|
|
</p><p>For more detailed information, please see the Methodology Review.</p><div id="ch5.appb.s1"><h4>B.1. Clinical search literature search strategy</h4><p>The search for this review was constructed using population terms. An
|
|
excluded studies filter was applied where appropriate.</p><p id="ch5.appb.tab1"><a href="/books/NBK578166/table/ch5.appb.tab1/?report=objectonly" target="object" rid-ob="figobch5appbtab1" class="figpopup">Table 6. Database date parameters and filters used</a></p><p id="ch5.appb.tab2"><a href="/books/NBK578166/table/ch5.appb.tab2/?report=objectonly" target="object" rid-ob="figobch5appbtab2" class="figpopup">Medline (Ovid) search terms</a></p><p id="ch5.appb.tab3"><a href="/books/NBK578166/table/ch5.appb.tab3/?report=objectonly" target="object" rid-ob="figobch5appbtab3" class="figpopup">Embase (Ovid) search terms</a></p><p id="ch5.appb.tab4"><a href="/books/NBK578166/table/ch5.appb.tab4/?report=objectonly" target="object" rid-ob="figobch5appbtab4" class="figpopup">Cochrane Library (Wiley) search terms</a></p></div><div id="ch5.appb.s2"><h4>B.2. Health Economics literature search strategy</h4><p>Health economic evidence was identified by conducting a broad search
|
|
relating to Lyme disease population in NHS Economic Evaluation
|
|
Database (NHS EED – this ceased to be updated after March
|
|
2015) and the Health Technology Assessment database (HTA) with no
|
|
date restrictions. NHS EED and HTA databases are hosted by the
|
|
Centre for Research and Dissemination (CRD). Additional searches
|
|
were run on Medline and Embase for health economics, economic
|
|
modelling and quality of life studies.</p><p id="ch5.appb.tab5"><a href="/books/NBK578166/table/ch5.appb.tab5/?report=objectonly" target="object" rid-ob="figobch5appbtab5" class="figpopup">Table 7. Database date parameters and filters used</a></p><p id="ch5.appb.tab6"><a href="/books/NBK578166/table/ch5.appb.tab6/?report=objectonly" target="object" rid-ob="figobch5appbtab6" class="figpopup">Medline (Ovid) search terms</a></p><p id="ch5.appb.tab7"><a href="/books/NBK578166/table/ch5.appb.tab7/?report=objectonly" target="object" rid-ob="figobch5appbtab7" class="figpopup">Embase (Ovid) search terms</a></p><p id="ch5.appb.tab8"><a href="/books/NBK578166/table/ch5.appb.tab8/?report=objectonly" target="object" rid-ob="figobch5appbtab8" class="figpopup">NHS EED and HTA (CRD) search terms</a></p></div></div><div id="ch5.appc"><h3>Appendix C. Clinical evidence selection</h3><p id="ch5.appc.fig1"><a href="/books/NBK578166/figure/ch5.appc.fig1/?report=objectonly" target="object" rid-ob="figobch5appcfig1" class="figpopup">Figure 1. Flow chart of clinical study selection for the reviews of the
|
|
management of specific clinical scenarios for Lyme
|
|
disease</a></p></div><div id="ch5.appd"><h3>Appendix D. Clinical evidence tables</h3><p>None.</p></div><div id="ch5.appe"><h3>Appendix E. Forest plots</h3><p>None.</p></div><div id="ch5.appf"><h3>Appendix F. GRADE tables</h3><p>None.</p></div><div id="ch5.appg"><h3>Appendix G. Health economic evidence selection</h3><p id="ch5.appg.fig1"><a href="/books/NBK578166/figure/ch5.appg.fig1/?report=objectonly" target="object" rid-ob="figobch5appgfig1" class="figpopup">Figure 2. Flow chart of economic study selection for the
|
|
guideline</a></p></div><div id="ch5.apph"><h3>Appendix H. Health economic evidence tables</h3><p>None.</p></div><div id="ch5.appi"><h3>Appendix I. Excluded studies</h3><div id="ch5.appi.s1"><h4>I.1. Excluded clinical studies</h4><p id="ch5.appi.tab1"><a href="/books/NBK578166/table/ch5.appi.tab1/?report=objectonly" target="object" rid-ob="figobch5appitab1" class="figpopup">Table 8. Studies excluded from the clinical management
|
|
reviews</a></p></div><div id="ch5.appi.s2"><h4>I.2. Excluded health economic studies</h4><p id="ch5.appi.tab2"><a href="/books/NBK578166/table/ch5.appi.tab2/?report=objectonly" target="object" rid-ob="figobch5appitab2" class="figpopup">Table 9. Studies excluded from the health economic review</a></p></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Intervention evidence review</p><p>This evidence review was developed by the National Guideline Centre</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of
|
|
NICE, arrived at after careful consideration of the evidence available. When
|
|
exercising their judgement, professionals are expected to take this guideline fully
|
|
into account, alongside the individual needs, preferences and values of their
|
|
patients or service users. The recommendations in this guideline are not mandatory
|
|
and the guideline does not override the responsibility of healthcare professionals
|
|
to make decisions appropriate to the circumstances of the individual patient, in
|
|
consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to
|
|
be applied when individual health professionals and their patients or service users
|
|
wish to use it. They should do so in the context of local and national priorities
|
|
for funding and developing services, and in light of their duties to have due regard
|
|
to the need to eliminate unlawful discrimination, to advance equality of opportunity
|
|
and to reduce health inequalities. Nothing in this guideline should be interpreted
|
|
in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in
|
|
other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and
|
|
<a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland
|
|
Executive</a>. All NICE guidance is subject to regular review and may be
|
|
updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2018.</div><div class="small"><span class="label">Bookshelf ID: NBK578166</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35201694" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">35201694</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobch5tab1"><div id="ch5.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_ch5.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_ch5.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Adults (18 years and over),
|
|
young people (12 to 17 years) and children (under 12
|
|
years) with Lyme disease determined by a diagnostic
|
|
test or clinical diagnosis who have non-specific
|
|
symptoms that may be related to Lyme disease. This
|
|
includes symptoms such as: <ul id="ch5.l1"><li id="ch5.lt1" class="half_rhythm"><div>disturbed cognitive function, for example,
|
|
memory loss</div></li><li id="ch5.lt2" class="half_rhythm"><div>dizziness</div></li><li id="ch5.lt3" class="half_rhythm"><div>fatigue</div></li><li id="ch5.lt4" class="half_rhythm"><div>fever and sweats</div></li><li id="ch5.lt5" class="half_rhythm"><div>headache</div></li><li id="ch5.lt6" class="half_rhythm"><div>lymphadenopathy</div></li><li id="ch5.lt7" class="half_rhythm"><div>myalgia and muscle stiffness</div></li><li id="ch5.lt8" class="half_rhythm"><div>neck pain or stiffness</div></li><li id="ch5.lt9" class="half_rhythm"><div>paraesthesia</div></li><li id="ch5.lt10" class="half_rhythm"><div>photophobia</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_ch5.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><td headers="hd_b_ch5.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Antimicrobials, including
|
|
but not limited to: <ul id="ch5.l2"><li id="ch5.lt11" class="half_rhythm"><div>Penicillins <ul id="ch5.l3" class="circle"><li id="ch5.lt12" class="half_rhythm"><div>Amoxicillin (oral, IV)</div></li><li id="ch5.lt13" class="half_rhythm"><div>Ampicillin (oral, IV)</div></li><li id="ch5.lt14" class="half_rhythm"><div>Benzylpenicillin sodium / Penicillin G (IV)
|
|
<dl id="ch5.l4" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="ch5.lt15"><p class="no_top_margin">Including Augmentin (Amoxicillin and clavulanic
|
|
acid; oral, IV)</p></dd></dl></dl></div></li><li id="ch5.lt16" class="half_rhythm"><div>Phenoxymethylpenicillin / Penicillin V
|
|
(oral)</div></li></ul></div></li><li id="ch5.lt17" class="half_rhythm"><div>Tetracyclines <ul id="ch5.l5" class="circle"><li id="ch5.lt18" class="half_rhythm"><div>Doxycycline (oral)</div></li><li id="ch5.lt19" class="half_rhythm"><div>Minocycline (oral)</div></li></ul></div></li><li id="ch5.lt20" class="half_rhythm"><div>Cephalosporins <ul id="ch5.l6" class="circle"><li id="ch5.lt21" class="half_rhythm"><div>Cefotaxime (IV)</div></li><li id="ch5.lt22" class="half_rhythm"><div>Ceftriaxone (IV)</div></li><li id="ch5.lt23" class="half_rhythm"><div>Cefuroxime axetil (oral)</div></li></ul></div></li><li id="ch5.lt24" class="half_rhythm"><div>Macrolides <ul id="ch5.l7" class="circle"><li id="ch5.lt25" class="half_rhythm"><div>Azithromycin (oral)</div></li><li id="ch5.lt26" class="half_rhythm"><div>Clarithromycin (oral, IV)</div></li></ul></div></li><li id="ch5.lt27" class="half_rhythm"><div>Fluoroquinolones <ul id="ch5.l8" class="circle"><li id="ch5.lt28" class="half_rhythm"><div>Ciprofloxacin (oral, IV)</div></li><li id="ch5.lt29" class="half_rhythm"><div>Levofloxacin (oral, IV)</div></li><li id="ch5.lt30" class="half_rhythm"><div>Moxifloxacin (oral, IV)</div></li><li id="ch5.lt31" class="half_rhythm"><div>Nalidixic acid (oral)</div></li><li id="ch5.lt32" class="half_rhythm"><div>Norfloxacin (oral)</div></li><li id="ch5.lt33" class="half_rhythm"><div>Ofloxacin (oral, IV)</div></li></ul></div></li><li id="ch5.lt34" class="half_rhythm"><div>Rifampicin (oral, IV)</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_ch5.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">• Comparisons</th><td headers="hd_b_ch5.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch5.l9"><li id="ch5.lt35" class="half_rhythm"><div>Antimicrobial agents compared with each other
|
|
<ul id="ch5.l10" class="circle"><li id="ch5.lt36" class="half_rhythm"><div>If data are available, consider: <dl id="ch5.l11" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="ch5.lt37"><p class="no_top_margin">Type of antimicrobial agent (within class or
|
|
between class)</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="ch5.lt38"><p class="no_top_margin">Route of administration</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="ch5.lt39"><p class="no_top_margin">Duration of treatment: 1 month versus
|
|
longer</p></dd></dl></dl></div></li></ul></div></li><li id="ch5.lt40" class="half_rhythm"><div>Monotherapy versus polytherapy (any
|
|
combination)</div></li><li id="ch5.lt41" class="half_rhythm"><div>Antimicrobial agents compared to no treatment /
|
|
placebo</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_ch5.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_ch5.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p><b>Critical:</b>
|
|
<dl id="ch5.l12" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd id="ch5.lt42"><p class="no_top_margin">Quality of life (any validated measure)</p></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd id="ch5.lt43"><p class="no_top_margin">Cure (resolution of symptoms)</p></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd id="ch5.lt44"><p class="no_top_margin">Reduction of clinical symptoms</p></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd id="ch5.lt45"><p class="no_top_margin">Symptom relapse</p></dd></dl></dl></p>
|
|
<p><b>Important:</b>
|
|
<dl id="ch5.l13" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>5.</dt><dd id="ch5.lt46"><p class="no_top_margin">Adverse events</p></dd></dl></dl></p></td></tr><tr><th id="hd_b_ch5.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_ch5.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Randomised control studies
|
|
(RCT)</p>
|
|
<p>Cohort studies (if no RCT evidence is
|
|
found)</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5tab2"><div id="ch5.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">UK costs of antimicrobials</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch5.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Class</th><th id="hd_h_ch5.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Drug</th><th id="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Age</th><th id="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Preparation</th><th id="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Mg/unit</th><th id="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost/unit
|
|
(£)</th><th id="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Units/day</th><th id="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Course duration
|
|
(days)</th><th id="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost per course
|
|
(£)</th></tr></thead><tbody><tr><td headers="hd_h_ch5.tab2_1_1_1_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:top;">Penicillins</td><td headers="hd_h_ch5.tab2_1_1_1_2" rowspan="3" colspan="1" style="text-align:left;vertical-align:top;">Amoxicillin</td><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7days-11 months</td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">125 mg/1.25 ml oral
|
|
suspension paediatric</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">125</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.20</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14–28</td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.35–16.70</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1–4 years</td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">250 mg/5 ml oral
|
|
suspension</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">250</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.06</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14–28</td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.37–4.75</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>5years</td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">capsules</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">500</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.06</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14–28<sup>(g)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.54–5.08</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Penicillins</td><td headers="hd_h_ch5.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Phenoxymethy
|
|
Ipenicillin</td><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults <sup>(a)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tablets</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">250</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.04</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.49</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tetracyclines</td><td headers="hd_h_ch5.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Doxycycline</td><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>12 years</td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">capsules</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.11</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10–28 <sup>(h)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.18–6.09</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cephalosporins</td><td headers="hd_h_ch5.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cefuroxime axetil</td><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>3months</td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tablets</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">250</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.27</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14–28 <sup>(g)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.88–141.76</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Macrolide</td><td headers="hd_h_ch5.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clarithromycin</td><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>1 month</td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tablets</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">500</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.16</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14–21</td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.42–6.63</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Macrolide</td><td headers="hd_h_ch5.tab2_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Azithromycin</td><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><12 years</td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 mg/1 ml oral
|
|
suspension</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.27</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 mg/kg</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9<sup>(i)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Weight dependent</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults</td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tablets</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">500</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.42</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9<sup>(i)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.75</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cephalosporins</td><td headers="hd_h_ch5.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cefotaxime</td><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults <sup>(b)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 g powder for solution
|
|
for injection vials (IV)</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2,000</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.75</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">112.50</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cephalosporins</td><td headers="hd_h_ch5.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ceftriaxone</td><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>9 years <sup>(c)</sup><sup>(d)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 g powder for solution
|
|
for injection vials (IV) <sup>(e)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2,000</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.03</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14–21</td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.42–21.63</td></tr><tr><td headers="hd_h_ch5.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Penicillins</td><td headers="hd_h_ch5.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Benzylpenicillin
|
|
sodium</td><td headers="hd_h_ch5.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults <sup>(f)</sup></td><td headers="hd_h_ch5.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">600 mg powder for solution
|
|
for injection vials (IM)</td><td headers="hd_h_ch5.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">600</td><td headers="hd_h_ch5.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.73</td><td headers="hd_h_ch5.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch5.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch5.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.38</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Abbreviations: IM: intramuscular; IV: intravenously.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Sources: Unit costs from NHS Electronic Drug Tariff January
|
|
2017,<a class="bibr" href="#ch5.ref117" rid="ch5.ref117"><sup>117</sup></a> except cefotaxime from BNF,
|
|
January 2017<a class="bibr" href="#ch5.ref20" rid="ch5.ref20"><sup>20</sup></a> and ceftriaxone from EMIT
|
|
March 2017;<a class="bibr" href="#ch5.ref37" rid="ch5.ref37"><sup>37</sup></a> dosage from BNF and BNF for
|
|
Children January 2017,<a class="bibr" href="#ch5.ref20" rid="ch5.ref20"><sup>20</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch5.ref21" rid="ch5.ref21"><sup>21</sup></a>
|
|
exceptions below:</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="ch5.tab2_1"><p class="no_margin">Source of dosage from RCT in adults with EM: Steere
|
|
1983,<a class="bibr" href="#ch5.ref184" rid="ch5.ref184"><sup>184</sup></a> dosage for Lyme disease not
|
|
available from BNF or BNF for children.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="ch5.tab2_2"><p class="no_margin">Source of dosage from RCT in adults with
|
|
neuroborreliosis: Pfister 1989<a class="bibr" href="#ch5.ref129" rid="ch5.ref129"><sup>129</sup></a> and Pfister
|
|
1991,<a class="bibr" href="#ch5.ref130" rid="ch5.ref130"><sup>130</sup></a> dosage for Lyme disease not
|
|
available from BNF or BNF for children. <a class="bibr" href="#ch5.ref20" rid="ch5.ref20"><sup>20</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch5.ref21" rid="ch5.ref21"><sup>21</sup></a></p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="ch5.tab2_3"><p class="no_margin">For disseminated Lyme borreliosis.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="ch5.tab2_4"><p class="no_margin">Dose for neonate and child up to 11 years (body weight
|
|
<50kg) 50–80 mg/kg once daily for
|
|
14–21 days. BNF for children January 2017<a class="bibr" href="#ch5.ref21" rid="ch5.ref21"><sup>21</sup></a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(e)</dt><dd><div id="ch5.tab2_5"><p class="no_margin">Administration can vary in adults and children >1
|
|
month: IV infusion over 30 mins or IV injection over 5
|
|
mins or deep muscular injection (doses over 1g divided
|
|
between more than 1 site): 2g per day for 14–21
|
|
days BNF January 2017.<a class="bibr" href="#ch5.ref20" rid="ch5.ref20"><sup>20</sup></a></p></div></dd></dl><dl class="bkr_refwrap"><dt>(f)</dt><dd><div id="ch5.tab2_6"><p class="no_margin">Source of dosage from RCT in adults with Lyme arthritis:
|
|
Steere 1985:<a class="bibr" href="#ch5.ref163" rid="ch5.ref163"><sup>163</sup></a> 1.2 million U injected in
|
|
each buttock weekly intramuscularly. Duration 3 weeks.
|
|
Dosage for Lyme disease not available from BNF or BNF
|
|
for children. <a class="bibr" href="#ch5.ref20" rid="ch5.ref20"><sup>20</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch5.ref21" rid="ch5.ref21"><sup>21</sup></a></p></div></dd></dl><dl class="bkr_refwrap"><dt>(g)</dt><dd><div id="ch5.tab2_7"><p class="no_margin">Course duration for early Lyme 14–21 days; 28 days
|
|
for Lyme arthritis. BNF January 2017.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(h)</dt><dd><div id="ch5.tab2_8"><p class="no_margin">Course duration for early Lyme 10–14 days; 28 days
|
|
for Lyme arthritis. BNF January 2017.<a class="bibr" href="#ch5.ref20" rid="ch5.ref20"><sup>20</sup></a></p></div></dd></dl><dl class="bkr_refwrap"><dt>(i)</dt><dd><div id="ch5.tab2_9"><p class="no_margin">Course dose and duration for adults: 500 mg once daily
|
|
for 3 days for 3 weeks. For children under 12 years, 10
|
|
mg/kg once daily for 3 days for 3 weeks. Committee
|
|
expert opinion.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch5tab3"><div id="ch5.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Unit costs of inpatient administration</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch5.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Schedule</th><th id="hd_h_ch5.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Currency
|
|
description</th><th id="hd_h_ch5.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Currency codes</th><th id="hd_h_ch5.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Weighted average
|
|
unit costs (per day)</th></tr></thead><tbody><tr><td headers="hd_h_ch5.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Day-case adults</td><td headers="hd_h_ch5.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard/major/complex
|
|
infectious diseases with/without single/multiple
|
|
interventions, with/without CC</td><td headers="hd_h_ch5.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">WJ01B, WJ01D, WJ01E,
|
|
WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C,
|
|
WJ03D, WJ03E, WJ03F, WJ03G</td><td headers="hd_h_ch5.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£352</td></tr><tr><td headers="hd_h_ch5.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Day-case
|
|
paediatrics</td><td headers="hd_h_ch5.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Paediatric
|
|
minor/major/intermediate infections with/without
|
|
CC</td><td headers="hd_h_ch5.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PW01A, PW01B, PW01C,
|
|
PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E,
|
|
PW17F, PW17G</td><td headers="hd_h_ch5.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£448</td></tr><tr><td headers="hd_h_ch5.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Non-elective inpatient
|
|
short-stay adults</td><td headers="hd_h_ch5.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard/major/complex
|
|
infectious diseases with/without single/multiple
|
|
interventions, with/without CC</td><td headers="hd_h_ch5.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">WJ01A, WJ01B, WJ01C,
|
|
WJ01D, WJ01E, WJ02A, WJ02B, WJ02C, WJ02D, WJ02E,
|
|
WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F,
|
|
WJ03G</td><td headers="hd_h_ch5.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£432</td></tr><tr><td headers="hd_h_ch5.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Non-elective inpatient
|
|
short-stay paediatrics</td><td headers="hd_h_ch5.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Paediatric
|
|
minor/major/intermediate infections with/without
|
|
CC</td><td headers="hd_h_ch5.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PW01A, PW01B, PW01C,
|
|
PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E,
|
|
PW17F, PW17G</td><td headers="hd_h_ch5.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£521</td></tr><tr><td headers="hd_h_ch5.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Non-elective inpatient
|
|
long-stay adults</td><td headers="hd_h_ch5.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard/major/complex
|
|
infectious diseases with/without single/multiple
|
|
interventions, with/without CC</td><td headers="hd_h_ch5.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">WJ01A, WJ01B, WJ01C,
|
|
WJ01D, WJ01E, WJ02A, WJ02B, WJ02C, WJ02D, WJ02E,
|
|
WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F,
|
|
WJ03G</td><td headers="hd_h_ch5.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£473</td></tr><tr><td headers="hd_h_ch5.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Non-elective inpatient
|
|
long-stay paediatrics</td><td headers="hd_h_ch5.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Paediatric
|
|
minor/major/intermediate infections with/without
|
|
CC</td><td headers="hd_h_ch5.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PW01A, PW01B, PW01C,
|
|
PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E,
|
|
PW17F, PW17G</td><td headers="hd_h_ch5.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£699</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Source: NHS reference costs 2015/2016<a class="bibr" href="#ch5.ref45" rid="ch5.ref45"><sup>45</sup></a></p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch5appatab1"><div id="ch5.appa.tab1" class="table"><h3><span class="label">Table 4</span><span class="title">Review protocol for the management of non-specific
|
|
symptoms</span></h3><div class="caption"><p>Question number: 4.1</p><p>Relevant section of Scope: management</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appa.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Field</th><th id="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Content</th></tr></thead><tbody><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">What is the most clinically
|
|
and cost-effective treatment for seropositive people,
|
|
who have non-specific symptoms that may be related to
|
|
Lyme disease?</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Type of review question</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention</p>
|
|
<p>A review
|
|
of health economic evidence related to the same
|
|
review question was conducted in parallel with this
|
|
review. For details, see the health economic review
|
|
protocol for this NICE guideline.</p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Objective of the review</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The review questions on the
|
|
condition-specific management of Lyme disease aim to
|
|
identify the most effective treatment in different
|
|
clinical scenarios. The questions have been developed in
|
|
a way to identify the evidence for all potential
|
|
populations and scenarios, even if clinical
|
|
presentations are more diverse. The population for this
|
|
review consists of people with a seropositive test
|
|
result for Lyme disease, who have non-specific symptoms
|
|
that may be related to Lyme disease.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria –
|
|
population / disease / condition</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Adults (18 years and over),
|
|
young people (12 to 17 years) and children (under 12
|
|
years) with Lyme disease determined by a diagnostic
|
|
tests or clinical diagnosis who have non-specific
|
|
symptoms that may be related to Lyme disease. This
|
|
includes symptoms such as: <ul id="ch5.l15"><li id="ch5.lt53" class="half_rhythm"><div>disturbed cognitive function, for example,
|
|
memory loss</div></li><li id="ch5.lt54" class="half_rhythm"><div>dizziness</div></li><li id="ch5.lt55" class="half_rhythm"><div>fatigue</div></li><li id="ch5.lt56" class="half_rhythm"><div>fever and sweats</div></li><li id="ch5.lt57" class="half_rhythm"><div>headache</div></li><li id="ch5.lt58" class="half_rhythm"><div>lymphadenopathy</div></li><li id="ch5.lt59" class="half_rhythm"><div>myalgia and muscle stiffness</div></li><li id="ch5.lt60" class="half_rhythm"><div>neck pain or stiffness</div></li><li id="ch5.lt61" class="half_rhythm"><div>paraesthesia</div></li><li id="ch5.lt62" class="half_rhythm"><div>photophobia</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria –
|
|
intervention(s)</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Antimicrobials, including
|
|
but not limited to: <ul id="ch5.l16"><li id="ch5.lt63" class="half_rhythm"><div>Penicillins <ul id="ch5.l17" class="circle"><li id="ch5.lt64" class="half_rhythm"><div>Amoxicillin (oral, IV)</div></li><li id="ch5.lt65" class="half_rhythm"><div>Ampicillin (oral, IV)</div></li><li id="ch5.lt66" class="half_rhythm"><div>Benzylpenicillin sodium / Penicillin G (IV)
|
|
<dl id="ch5.l18" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="ch5.lt67"><p class="no_top_margin">Including Augmentin (Amoxicillin and clavulanic
|
|
acid; oral, IV)</p></dd></dl></dl></div></li><li id="ch5.lt68" class="half_rhythm"><div>Phenoxymethylpenicillin / Penicillin V
|
|
(oral)</div></li></ul></div></li><li id="ch5.lt69" class="half_rhythm"><div>Tetracyclines <ul id="ch5.l19" class="circle"><li id="ch5.lt70" class="half_rhythm"><div>Doxycycline (oral)</div></li><li id="ch5.lt71" class="half_rhythm"><div>Minocycline (oral)</div></li></ul></div></li><li id="ch5.lt72" class="half_rhythm"><div>Cephalosporins <ul id="ch5.l20" class="circle"><li id="ch5.lt73" class="half_rhythm"><div>Cefotaxime (IV)</div></li><li id="ch5.lt74" class="half_rhythm"><div>Ceftriaxone (IV)</div></li><li id="ch5.lt75" class="half_rhythm"><div>Cefuroxime axetil (oral)</div></li></ul></div></li><li id="ch5.lt76" class="half_rhythm"><div>Macrolides <ul id="ch5.l21" class="circle"><li id="ch5.lt77" class="half_rhythm"><div>Azithromycin (oral)</div></li><li id="ch5.lt78" class="half_rhythm"><div>Clarithromycin (oral, IV)</div></li></ul></div></li><li id="ch5.lt79" class="half_rhythm"><div>Fluoroquinolones <ul id="ch5.l22" class="circle"><li id="ch5.lt80" class="half_rhythm"><div>Ciprofloxacin (oral, IV)</div></li><li id="ch5.lt81" class="half_rhythm"><div>Levofloxacin (oral, IV)</div></li><li id="ch5.lt82" class="half_rhythm"><div>Moxifloxacin (oral, IV)</div></li><li id="ch5.lt83" class="half_rhythm"><div>Nalidixic acid (oral)</div></li><li id="ch5.lt84" class="half_rhythm"><div>Norfloxacin (oral)</div></li><li id="ch5.lt85" class="half_rhythm"><div>Ofloxacin (oral, IV)</div></li></ul></div></li><li id="ch5.lt86" class="half_rhythm"><div>Rifampicin (oral, IV)</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria –
|
|
comparator(s)</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch5.l23"><li id="ch5.lt87" class="half_rhythm"><div>Antimicrobial agents compared with each other
|
|
<ul id="ch5.l24" class="circle"><li id="ch5.lt88" class="half_rhythm"><div>If data are available, consider: <dl id="ch5.l25" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="ch5.lt89"><p class="no_top_margin">Type of antimicrobial agent (within class or
|
|
between class)</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="ch5.lt90"><p class="no_top_margin">Route of administration</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="ch5.lt91"><p class="no_top_margin">Duration of treatment: 1 month versus
|
|
longer</p></dd></dl></dl></div></li></ul></div></li><li id="ch5.lt92" class="half_rhythm"><div>Monotherapy versus polytherapy (any
|
|
combination)</div></li><li id="ch5.lt93" class="half_rhythm"><div>Antimicrobial agents compared to no treatment /
|
|
placebo</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes and
|
|
prioritisation</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p><b>Critical:</b>
|
|
<dl id="ch5.l26" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd id="ch5.lt94"><p class="no_top_margin">Quality of life (any validated measure)</p></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd id="ch5.lt95"><p class="no_top_margin">Cure (resolution of symptoms)</p></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd id="ch5.lt96"><p class="no_top_margin">Reduction of clinical symptoms</p></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd id="ch5.lt97"><p class="no_top_margin">Symptom relapse</p></dd></dl></dl></p>
|
|
<p><b>Important:</b>
|
|
<dl id="ch5.l27" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>5.</dt><dd id="ch5.lt98"><p class="no_top_margin">Adverse events</p></dd></dl></dl></p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria - study
|
|
design</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RCTs</p>
|
|
<p>Cohort studies
|
|
(if no RCT evidence is found)</p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other inclusion exclusion
|
|
criteria</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Date limits for search:
|
|
none</p><p>Language: English only</p><p>Setting: all
|
|
settings in which NHS is care is provided or
|
|
commissioned</p><p>The following interventions will
|
|
not be considered for inclusion: <ul id="ch5.l28"><li id="ch5.lt99" class="half_rhythm"><div>Metronidazole</div></li><li id="ch5.lt100" class="half_rhythm"><div>Trimethoprim</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proposed sensitivity /
|
|
subgroup analysis, or meta-regression</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>The following groups will
|
|
be considered separately if data are available
|
|
(strata): <ul id="ch5.l29"><li id="ch5.lt101" class="half_rhythm"><div>Children (under 12 years); young people and
|
|
adults (12 years and over)</div></li><li id="ch5.lt102" class="half_rhythm"><div>Onset of specific symptoms less than 6 weeks; 6
|
|
weeks to 6 months; over 6 months</div></li></ul></p>
|
|
<p>Subgroups (to be investigated if heterogeneity is
|
|
identified): <ul id="ch5.l30"><li id="ch5.lt103" class="half_rhythm"><div>Pregnant women</div></li><li id="ch5.lt104" class="half_rhythm"><div>People who are immunocompromised</div></li><li id="ch5.lt105" class="half_rhythm"><div>People in whom a previous course of
|
|
antimicrobial treatment has failed</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selection process –
|
|
duplicate screening / selection / analysis</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Studies will be sifted by
|
|
title and abstract. Potentially significant publications
|
|
obtained in full text will then be assessed against the
|
|
inclusion criteria specified in this protocol.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data management
|
|
(software)</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Pairwise meta-analyses will
|
|
be performed using Cochrane Review Manager
|
|
(RevMan5).</p>
|
|
<p>GRADEpro will be used to assess the
|
|
quality of evidence for each
|
|
outcome</p>
|
|
<p>Bibliographies, citations, study
|
|
sifting and reference management will be managed
|
|
using EndNote.</p>
|
|
<p>Data extractions will be
|
|
performed using EviBase, a platform designed and
|
|
maintained by the National Guideline Centre
|
|
(NGC)</p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Information sources –
|
|
databases and dates</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Clinical
|
|
searches</p>
|
|
<p>Medline, Embase, The Cochrane Library
|
|
all years</p>
|
|
<p>Health economic
|
|
searches</p>
|
|
<p>Medline, Embase, NHS Economic
|
|
Evaluation Database (NHS EED), Health Technology
|
|
Assessment (HTA) all years</p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Identify if an update</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not applicable</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Author contacts</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10007" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.nice.org<wbr style="display:inline-block"></wbr>​.uk/guidance/indevelopment/gid-ng10007</a>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Highlight if amendment to
|
|
previous protocol</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see
|
|
section 4.5 of <a href="https://www.nice.org.uk/article/pmg20/chapter/4-Developing-review-questions-and-planning-the-evidence-review#planning-the-evidence-review" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the
|
|
manual</a>.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search strategy - for one
|
|
database</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see <a href="#ch5.appb">appendix B</a></td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data collection process
|
|
– forms / duplicate</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A standardised evidence table
|
|
format will be used, and published as <a href="#ch5.appd">appendix D</a> of
|
|
the evidence report.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data items - define all
|
|
variables to be collected</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see
|
|
evidence tables in <a href="#ch5.appd">Appendix D</a> (clinical evidence tables) or
|
|
<a href="#ch5.apph">H</a> (health
|
|
economic evidence tables).</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for assessing bias at
|
|
outcome / study level</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Standard study checklists
|
|
were used to appraise critically individual studies.
|
|
For details, please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the
|
|
manual</a></p>
|
|
<p>The risk of bias across all available evidence will
|
|
be evaluated for each outcome using an adaptation of
|
|
the ‘Grading of Recommendations Assessment,
|
|
Development and Evaluation (GRADE) toolbox’
|
|
developed by the international GRADE working group
|
|
<a href="http://www.gradeworkinggroup.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.gradeworkinggroup.org/</a></p></td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Criteria for quantitative
|
|
synthesis</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>For details, please see
|
|
section 6.4 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the
|
|
manual</a>.</p>
|
|
<p>Meta-analysis will be
|
|
conducted wherever possible (that is, where similar
|
|
studies can be combined)</p>
|
|
<p>In the absence of
|
|
clinically established MIDs, standard MIDsfor
|
|
dichotomous (25% risk reduction or risk increase)
|
|
and continuous outcomes (+/-0.5 standard deviation)
|
|
will be used If heterogeneity is found, the
|
|
influence of subgroups will be examined</p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for quantitative
|
|
analysis-combining studies and exploring
|
|
(in)consistency</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see the
|
|
separate Methods report for this guideline.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-bias assessment –
|
|
publication bias, selective reporting bias</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see
|
|
section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the
|
|
manual</a>.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Confidence in cumulative
|
|
evidence</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see
|
|
sections 6.4 and 9.1 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the
|
|
manual</a>.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rationale/context-what is
|
|
known</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see the
|
|
introduction to the evidence review.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describe contributions of
|
|
authors and guarantor</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>A <a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10007/documents" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">multidisciplinary committee</a> developed
|
|
the evidence review. The committee was convened by
|
|
the NGC and chaired by Saul Faust in line with
|
|
section 3 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the
|
|
manual</a>.</p>
|
|
<p>Staff from the NGC
|
|
undertook systematic literature searches, appraised
|
|
the evidence, conducted meta-analysis and
|
|
cost-effectiveness analysis where appropriate, and
|
|
drafted the evidence review in collaboration with
|
|
the committee. For details, please see <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the
|
|
manual</a>.</p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sources of funding /
|
|
support</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The NGC is funded by NICE and
|
|
hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Name of sponsor</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The NGC is funded by NICE and
|
|
hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roles of sponsor</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NICE funds the NGC to develop
|
|
guidelines for those working in the NHS, public health
|
|
and social care in England.</td></tr><tr><td headers="hd_h_ch5.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROSPERO registration
|
|
number</td><td headers="hd_h_ch5.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not registered</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appatab2"><div id="ch5.appa.tab2" class="table"><h3><span class="label">Table 5</span><span class="title">Health economic review protocol</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appa.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appa.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch5.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Review question</th><th id="hd_h_ch5.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All questions –
|
|
health economic evidence</th></tr></thead><tbody><tr><td headers="hd_h_ch5.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Objectives</b>
|
|
</td><td headers="hd_h_ch5.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To identify health economic
|
|
studies relevant to any of the review questions.</td></tr><tr><td headers="hd_h_ch5.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search
|
|
criteria</b>
|
|
</td><td headers="hd_h_ch5.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch5.l31"><li id="ch5.lt106" class="half_rhythm"><div>Populations, interventions and comparators must
|
|
be as specified in the clinical review protocol
|
|
above.</div></li><li id="ch5.lt107" class="half_rhythm"><div>Studies must be of a relevant health economic
|
|
study design (cost–utility analysis,
|
|
cost-effectiveness analysis, cost–benefit
|
|
analysis, cost–consequences analysis,
|
|
comparative cost analysis).</div></li><li id="ch5.lt108" class="half_rhythm"><div>Studies must not be a letter, editorial or
|
|
commentary, or a review of health economic
|
|
evaluations. (Recent reviews will be ordered
|
|
although not reviewed. The bibliographies will be
|
|
checked for relevant studies, which will then be
|
|
ordered.)</div></li><li id="ch5.lt109" class="half_rhythm"><div>Unpublished reports will not be considered
|
|
unless submitted as part of a call for
|
|
evidence.</div></li><li id="ch5.lt110" class="half_rhythm"><div>Studies must be in English.</div></li></ul></td></tr><tr><td headers="hd_h_ch5.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search
|
|
strategy</b>
|
|
</td><td headers="hd_h_ch5.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A health economic study search
|
|
will be undertaken using population-specific terms and a
|
|
health economic study filter – see <a href="#ch5.appb">appendix B</a>
|
|
below.</td></tr><tr><td headers="hd_h_ch5.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Review
|
|
strategy</b>
|
|
</td><td headers="hd_h_ch5.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Studies not meeting any of
|
|
the search criteria above will be excluded. Studies
|
|
published before 2001, abstract-only studies and
|
|
studies from non-OECD countries or the US will also
|
|
be excluded.</p>
|
|
<p>Each remaining study will be
|
|
assessed for applicability and methodological
|
|
limitations using the NICE economic evaluation
|
|
checklist which can be found in <a href="#ch5.apph">appendix H</a> of Developing
|
|
NICE guidelines: the manual (2014).<a class="bibr" href="#ch5.ref115" rid="ch5.ref115"><sup>115</sup></a></p>
|
|
<p><b>Inclusion and
|
|
exclusion criteria</b>
|
|
<ul id="ch5.l32"><li id="ch5.lt111" class="half_rhythm"><div>If a study is rated as both ‘Directly
|
|
applicable’ and with ‘Minor
|
|
limitations’, then it will be included in
|
|
the guideline. A health economic evidence table
|
|
will be completed and it will be included in the
|
|
health economic evidence profile.</div></li><li id="ch5.lt112" class="half_rhythm"><div>If a study is rated as either ‘Not
|
|
applicable’ or with ‘Very serious
|
|
limitations’ then it will usually be
|
|
excluded from the guideline. If it is excluded,
|
|
then a health economic evidence table will not be
|
|
completed and it will not be included in the
|
|
health economic evidence profile.</div></li><li id="ch5.lt113" class="half_rhythm"><div>If a study is rated as ‘Partially
|
|
applicable’, with ‘Potentially
|
|
serious limitations’ or both, then there is
|
|
discretion over whether it should be included.</div></li></ul>
|
|
<b>Where there is discretion</b></p>
|
|
<p>The
|
|
health economist will make a decision based on the
|
|
relative applicability and quality of the available
|
|
evidence for that question, in discussion with the
|
|
guideline committee if required. The ultimate aim is
|
|
to include health economic studies that are helpful
|
|
for decision-making in the context of the guideline
|
|
and the current NHS setting. If several studies are
|
|
considered of sufficiently high applicability and
|
|
methodological quality that they could all be
|
|
included, then the health economist, in discussion
|
|
with the committee if required, may decide to
|
|
include only the most applicable studies and to
|
|
exclude the remaining studies selectively. All
|
|
studies excluded based on applicability or
|
|
methodological limitations will be listed with
|
|
explanation in the excluded health economic studies
|
|
appendix below.</p>
|
|
<p>The health economist will be
|
|
guided by the following
|
|
hierarchies.</p>
|
|
<p><i>Setting:</i>
|
|
<ul id="ch5.l33"><li id="ch5.lt114" class="half_rhythm"><div>UK NHS (most applicable).</div></li><li id="ch5.lt115" class="half_rhythm"><div>OECD countries with predominantly public health
|
|
insurance systems (for example, France, Germany,
|
|
Sweden).</div></li><li id="ch5.lt116" class="half_rhythm"><div>OECD countries with predominantly private
|
|
health insurance systems (for example,
|
|
Switzerland).</div></li><li id="ch5.lt117" class="half_rhythm"><div>Studies set in non-OECD countries or in the US
|
|
will be excluded before being assessed for
|
|
applicability and methodological limitations.</div></li></ul> Health economic study type: <ul id="ch5.l34"><li id="ch5.lt118" class="half_rhythm"><div>Cost–utility analysis (most
|
|
applicable).</div></li><li id="ch5.lt119" class="half_rhythm"><div>Other type of full economic evaluation
|
|
(cost–benefit analysis, cost-effectiveness
|
|
analysis, cost–consequences analysis).</div></li><li id="ch5.lt120" class="half_rhythm"><div>Comparative cost analysis.</div></li><li id="ch5.lt121" class="half_rhythm"><div>Non-comparative cost analyses including
|
|
cost-of-illness studies will be excluded before
|
|
being assessed for applicability and
|
|
methodological limitations.</div></li></ul> Year of analysis: <ul id="ch5.l35"><li id="ch5.lt122" class="half_rhythm"><div>The more recent the study, the more applicable
|
|
it will be.</div></li><li id="ch5.lt123" class="half_rhythm"><div>Studies published in 2001 or later but that
|
|
depend on unit costs and resource data entirely or
|
|
predominantly before 2001 will be rated as
|
|
‘Not applicable’.</div></li><li id="ch5.lt124" class="half_rhythm"><div>Studies published before 2001 will be excluded
|
|
before being assessed for applicability and
|
|
methodological limitations.</div></li></ul> Quality and relevance of effectiveness data
|
|
used in the health economic analysis: <ul id="ch5.l36"><li id="ch5.lt125" class="half_rhythm"><div>The more closely the clinical effectiveness
|
|
data used in the health economic analysis match
|
|
with the outcomes of the studies included in the
|
|
clinical review the more useful the analysis will
|
|
be for decision-making in the guideline.</div></li></ul></p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appbtab1"><div id="ch5.appb.tab1" class="table"><h3><span class="label">Table 6</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch5.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Database</th><th id="hd_h_ch5.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dates searched</th><th id="hd_h_ch5.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_ch5.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline (OVID)</td><td headers="hd_h_ch5.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1946 – 03 July
|
|
2017</td><td headers="hd_h_ch5.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusions</td></tr><tr><td headers="hd_h_ch5.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase (OVID)</td><td headers="hd_h_ch5.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1974 – 03 July
|
|
2017</td><td headers="hd_h_ch5.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusions</td></tr><tr><td headers="hd_h_ch5.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The Cochrane Library
|
|
(Wiley)</td><td headers="hd_h_ch5.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Cochrane Reviews to
|
|
2017 Issue 7 of 12</p>
|
|
<p>CENTRAL to 2017 Issue 6
|
|
of 12</p>
|
|
<p>DARE, and NHSEED to 2015 Issue 2 of
|
|
4</p>
|
|
<p>HTA to 2016 Issue 4 of 4</p>
|
|
</td><td headers="hd_h_ch5.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appbtab2"><div id="ch5.appb.tab2" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appb.tab2_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Borrelia
|
|
Infections/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Lyme disease/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Erythema Chronicum
|
|
Migrans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(erythema adj3
|
|
migrans).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">lyme*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(tick* adj2 (bite* or
|
|
bitten or biting or borne)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acrodermatitis chronica
|
|
atrophicans.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Ixodidae/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(borreliosis or borrelia*
|
|
or neuroborreliosis or ixodid or ixodidae or ixodes
|
|
or b burgdorferi or b afzelii or b garinii or b
|
|
bissettii or b valaisiana or b microti).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(granulocyctic
|
|
anaplasmosis or babesia or babesiosis).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–10</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical
|
|
article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or
|
|
comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/12–18</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled
|
|
trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 not 20</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals,
|
|
Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal
|
|
Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or
|
|
mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/21–27</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 not 28</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 29 to English
|
|
language</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appbtab3"><div id="ch5.appb.tab3" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appb.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appb.tab3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Borrelia
|
|
Infection/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Lyme disease/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Erythema Chronicum
|
|
Migrans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(erythema adj3
|
|
migrans).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">lyme*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(tick* adj2 (bite* or
|
|
bitten or biting or borne)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acrodermatitis chronica
|
|
atrophicans.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Ixodidae/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(borreliosis or borrelia*
|
|
or neuroborreliosis or ixodidae or ixodes or b
|
|
burgdorferi or b afzelii or b garinii or b bissettii
|
|
or b valaisiana or b microti).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(granulocyctic
|
|
anaplasmosis or babesia or babesiosis).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–10</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or
|
|
comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/12–15</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled
|
|
trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 not 17</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal
|
|
Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental
|
|
animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or
|
|
mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18–25</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 not 26</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 27 to English
|
|
language</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appbtab4"><div id="ch5.appb.tab4" class="table"><h3><span class="title">Cochrane Library (Wiley) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appb.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appb.tab4_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Borrelia
|
|
Infections] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Lyme
|
|
Disease] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Erythema
|
|
Chronicum Migrans] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(erythema near/3
|
|
migrans):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">lyme*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(tick* near/2 (bite* or
|
|
bitten or biting or borne)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acrodermatitis chronica
|
|
atrophicans:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor:
|
|
[Ixodidae] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(borreliosis or borrelia*
|
|
or neuroborreliosis or ixodidae or ixodes or ixodid
|
|
or b burgdorferi or b afzelii or b garinii or b
|
|
bissettii or b valaisiana or b microti):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(granulocyctic
|
|
anaplasmosis or babesia or babesiosis):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 or #2 or #3 or #4 or #5
|
|
or #6 or #7 or #8 or #9 or #10</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appbtab5"><div id="ch5.appb.tab5" class="table"><h3><span class="label">Table 7</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appb.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appb.tab5_lrgtbl__"><table><thead><tr><th id="hd_h_ch5.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Database</th><th id="hd_h_ch5.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dates searched</th><th id="hd_h_ch5.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_ch5.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline</td><td headers="hd_h_ch5.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1946 – 03 July
|
|
2017</td><td headers="hd_h_ch5.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health
|
|
economics studies</p>
|
|
<p>Health economics modelling
|
|
studies</p>
|
|
<p>Quality of life studies</p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase</td><td headers="hd_h_ch5.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1974 – 03 July
|
|
2017</td><td headers="hd_h_ch5.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health
|
|
economics studies</p>
|
|
<p>Health economics modelling
|
|
studies</p>
|
|
<p>Quality of life studies</p>
|
|
</td></tr><tr><td headers="hd_h_ch5.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Centre for Research and
|
|
Dissemination (CRD)</td><td headers="hd_h_ch5.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HTA - Inception
|
|
– 03 July 2017</p>
|
|
<p>NHSEED - Inception to
|
|
March 2015</p>
|
|
</td><td headers="hd_h_ch5.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appbtab6"><div id="ch5.appb.tab6" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appb.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appb.tab6_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Borrelia
|
|
Infections/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Lyme disease/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Erythema Chronicum
|
|
Migrans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(erythema adj3
|
|
migrans).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">lyme*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(tick* adj2 (bite* or
|
|
bitten or biting or borne)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acrodermatitis chronica
|
|
atrophicans.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Ixodidae/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(borreliosis or borrelia*
|
|
or neuroborreliosis or ixodid or ixodidae or ixodes
|
|
or b burgdorferi or b afzelii or b garinii or b
|
|
bissettii or b valaisiana or b microti).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(granulocyctic
|
|
anaplasmosis or babesia or babesiosis).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–10</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical
|
|
article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or
|
|
comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/12–18</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled
|
|
trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 not 20</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals,
|
|
Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal
|
|
Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or
|
|
mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/21–27</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 not 28</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 29 to English
|
|
language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Value of life/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Costs and Cost
|
|
Analysis”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics,
|
|
Hospital/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics,
|
|
Medical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics, Nursing/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics,
|
|
Pharmaceutical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Fees and
|
|
Charges”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Budgets/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or
|
|
pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or
|
|
pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or
|
|
utilit* or benefit* or minimi* or unit* or estimat*
|
|
or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or
|
|
fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or
|
|
monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/31–46</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp models, economic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*Models, Theoretical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*Models,
|
|
Organizational/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">markov chains/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">monte carlo method/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Decision Theory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(markov* or monte
|
|
carlo).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">econom* model*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(decision* adj2 (tree* or
|
|
analy* or model*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/48–56</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">quality-adjusted life
|
|
years/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact
|
|
profile/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(quality adj2 (wellbeing
|
|
or well being)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact
|
|
profile.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">disability adjusted
|
|
life.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qal* or qtime* or qwb* or
|
|
daly*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(euroqol* or eq5d* or eq
|
|
5*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qol* or hql* or hqol* or
|
|
h qol* or hrqol* or hr qol*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health utility* or
|
|
utility score* or disutilit* or utility
|
|
value*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(hui or hui1 or hui2 or
|
|
hui3).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health* year* equivalent*
|
|
or hye or hyes).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">discrete
|
|
choice*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">rosser.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(willingness to pay or
|
|
time tradeoff or time trade off or tto or standard
|
|
gamble*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf36* or sf 36* or short
|
|
form 36* or shortform 36* or
|
|
shortform36*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf20 or sf 20 or short
|
|
form 20 or shortform 20 or shortform20).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf12* or sf 12* or short
|
|
form 12* or shortform 12* or
|
|
shortform12*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf8* or sf 8* or short
|
|
form 8* or shortform 8* or shortform8*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf6* or sf 6* or short
|
|
form 6* or shortform 6* or shortform6*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/58–76</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 and 47</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 and 57</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 and 77</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appbtab7"><div id="ch5.appb.tab7" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appb.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appb.tab7_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Borrelia
|
|
Infection/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Lyme disease/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Erythema Chronicum
|
|
Migrans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(erythema adj3
|
|
migrans).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">lyme*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(tick* adj2 (bite* or
|
|
bitten or biting or borne)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acrodermatitis chronica
|
|
atrophicans.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Ixodidae/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(borreliosis or borrelia*
|
|
or neuroborreliosis or ixodidae or ixodes or b
|
|
burgdorferi or b afzelii or b garinii or b bissettii
|
|
or b valaisiana or b microti).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(granulocyctic
|
|
anaplasmosis or babesia or babesiosis).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–10</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Case report/ or Case
|
|
study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or
|
|
comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/12–16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled
|
|
trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 18</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal
|
|
Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental
|
|
animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or
|
|
mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/19–26</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 not 27</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 28 to English
|
|
language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">health economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp economic
|
|
evaluation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp health care cost/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp fee/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">funding/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or
|
|
pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or
|
|
pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or
|
|
utilit* or benefit* or minimi* or unit* or estimat*
|
|
or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or
|
|
fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or
|
|
monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/30–42</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">statistical model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp economic aspect/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44 and 45</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*theoretical model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*nonbiological model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">stochastic model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">decision theory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">decision tree/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">monte carlo method/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(markov* or monte
|
|
carlo).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">econom* model*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(decision* adj2 (tree* or
|
|
analy* or model*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/46–55</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">quality adjusted life
|
|
year/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">"quality of life
|
|
index"/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">short form 12/ or short
|
|
form 20/ or short form 36/ or short form 8/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact
|
|
profile/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(quality adj2 (wellbeing
|
|
or well being)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact
|
|
profile.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">disability adjusted
|
|
life.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qal* or qtime* or qwb* or
|
|
daly*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(euroqol* or eq5d* or eq
|
|
5*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qol* or hql* or hqol* or
|
|
h qol* or hrqol* or hr qol*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health utility* or
|
|
utility score* or disutilit* or utility
|
|
value*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(hui or hui1 or hui2 or
|
|
hui3).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health* year* equivalent*
|
|
or hye or hyes).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">discrete
|
|
choice*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">rosser.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(willingness to pay or
|
|
time tradeoff or time trade off or tto or standard
|
|
gamble*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf36* or sf 36* or short
|
|
form 36* or shortform 36* or
|
|
shortform36*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf20 or sf 20 or short
|
|
form 20 or shortform 20 or shortform20).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf12* or sf 12* or short
|
|
form 12* or shortform 12* or
|
|
shortform12*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf8* or sf 8* or short
|
|
form 8* or shortform 8* or shortform8*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf6* or sf 6* or short
|
|
form 6* or shortform 6* or shortform6*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/57–77</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29 and 43</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29 and 56</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29 and 78</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appbtab8"><div id="ch5.appb.tab8" class="table"><h3><span class="title">NHS EED and HTA (CRD) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appb.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appb.tab8_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Borrelia
|
|
Infections EXPLODE ALL TREES IN NHSEED,HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Erythema
|
|
Chronicum Migrans EXPLODE ALL TREES IN
|
|
NHSEED,HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((erythema adj3 migrans))
|
|
IN NHSEED, HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(lyme*) IN NHSEED,
|
|
HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((tick* adj2 (bite* or
|
|
bitten or biting or borne))) IN NHSEED, HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acrodermatitis chronica
|
|
atrophicans) IN NHSEED, HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Ixodidae
|
|
EXPLODE ALL TREES IN NHSEED,HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((borreliosis or borrelia*
|
|
or neuroborreliosis or ixodidae or ixodes or b
|
|
burgdorferi or b afzelii or b garinii or b bissettii
|
|
or b valaisiana or b microti)) IN NHSEED, HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((granulocyctic
|
|
anaplasmosis or babesia or babesiosis)) IN NHSEED,
|
|
HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Lyme
|
|
Disease EXPLODE ALL TREES IN NHSEED,HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 OR #2 OR #3 OR #4 OR #5
|
|
OR #6 OR #7 OR #8 OR #9 OR #10</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobch5appcfig1"><div id="ch5.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Flow%20chart%20of%20clinical%20study%20selection%20for%20the%20reviews%20of%20the%20management%20of%20specific%20clinical%20scenarios%20for%20Lyme%20disease.&p=BOOKS&id=578166_ch5appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578166/bin/ch5appcf1.jpg" alt="Figure 1. Flow chart of clinical study selection for the reviews of the management of specific clinical scenarios for Lyme disease." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Flow chart of clinical study selection for the reviews of the
|
|
management of specific clinical scenarios for Lyme
|
|
disease</span></h3></div></article><article data-type="fig" id="figobch5appgfig1"><div id="ch5.appg.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%202.%20Flow%20chart%20of%20economic%20study%20selection%20for%20the%20guideline.&p=BOOKS&id=578166_ch5appgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578166/bin/ch5appgf1.jpg" alt="Figure 2. Flow chart of economic study selection for the guideline." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 2</span><span class="title">Flow chart of economic study selection for the
|
|
guideline</span></h3><div class="caption"><p>* Non-relevant population, intervention, comparison, design or
|
|
setting; non-English language</p></div></div></article><article data-type="table-wrap" id="figobch5appitab1"><div id="ch5.appi.tab1" class="table"><h3><span class="label">Table 8</span><span class="title">Studies excluded from the clinical management
|
|
reviews</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appi.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appi.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th><th id="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reason for
|
|
exclusion</th></tr></thead><tbody><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Aberer 2006<a class="bibr" href="#ch5.ref1" rid="ch5.ref1"><sup>1</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abrutyn 1989<a class="bibr" href="#ch5.ref2" rid="ch5.ref2"><sup>2</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Agger 1992<a class="bibr" href="#ch5.ref3" rid="ch5.ref3"><sup>3</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Agus 1995<a class="bibr" href="#ch5.ref4" rid="ch5.ref4"><sup>4</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Agwuh 2006<a class="bibr" href="#ch5.ref5" rid="ch5.ref5"><sup>5</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ahmed 2005<a class="bibr" href="#ch5.ref6" rid="ch5.ref6"><sup>6</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ahmed 2013<a class="bibr" href="#ch5.ref7" rid="ch5.ref7"><sup>7</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alarcon 1994<a class="bibr" href="#ch5.ref8" rid="ch5.ref8"><sup>8</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Andiman 1986<a class="bibr" href="#ch5.ref9" rid="ch5.ref9"><sup>9</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Anonymous 1991<a class="bibr" href="#ch5.ref10" rid="ch5.ref10"><sup>10</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Arvikar 2015<a class="bibr" href="#ch5.ref11" rid="ch5.ref11"><sup>11</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Auwaerter 2004<a class="bibr" href="#ch5.ref12" rid="ch5.ref12"><sup>12</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bennet 2003<a class="bibr" href="#ch5.ref13" rid="ch5.ref13"><sup>13</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Berende 2014<a class="bibr" href="#ch5.ref14" rid="ch5.ref14"><sup>14</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Berger 1988<a class="bibr" href="#ch5.ref16" rid="ch5.ref16"><sup>16</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Berger 1986<a class="bibr" href="#ch5.ref15" rid="ch5.ref15"><sup>15</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bernardino 2009<a class="bibr" href="#ch5.ref17" rid="ch5.ref17"><sup>17</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bhate 2011<a class="bibr" href="#ch5.ref18" rid="ch5.ref18"><sup>18</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bjark 2016<a class="bibr" href="#ch5.ref19" rid="ch5.ref19"><sup>19</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not available</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Borg 2005<a class="bibr" href="#ch5.ref22" rid="ch5.ref22"><sup>22</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bratton 2008<a class="bibr" href="#ch5.ref23" rid="ch5.ref23"><sup>23</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bremell 2014<a class="bibr" href="#ch5.ref24" rid="ch5.ref24"><sup>24</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">British Infection
|
|
Association 2011<a class="bibr" href="#ch5.ref25" rid="ch5.ref25"><sup>25</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Butler 1978<a class="bibr" href="#ch5.ref26" rid="ch5.ref26"><sup>26</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cadavid 2016<a class="bibr" href="#ch5.ref27" rid="ch5.ref27"><sup>27</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Canadian Paediatric
|
|
Society 1992<a class="bibr" href="#ch5.ref28" rid="ch5.ref28"><sup>28</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chen 1999<a class="bibr" href="#ch5.ref30" rid="ch5.ref30"><sup>30</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Choo-Kang 2010<a class="bibr" href="#ch5.ref31" rid="ch5.ref31"><sup>31</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Christian 1992<a class="bibr" href="#ch5.ref32" rid="ch5.ref32"><sup>32</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cimmino 1992<a class="bibr" href="#ch5.ref34" rid="ch5.ref34"><sup>34</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cimmino 1997<a class="bibr" href="#ch5.ref33" rid="ch5.ref33"><sup>33</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cimperman 1999<a class="bibr" href="#ch5.ref35" rid="ch5.ref35"><sup>35</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coblyn 1981<a class="bibr" href="#ch5.ref36" rid="ch5.ref36"><sup>36</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Committee on Infectious
|
|
Diseases 1991<a class="bibr" href="#ch5.ref38" rid="ch5.ref38"><sup>38</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cuisset 2008<a class="bibr" href="#ch5.ref39" rid="ch5.ref39"><sup>39</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dattwyler 1996<a class="bibr" href="#ch5.ref41" rid="ch5.ref41"><sup>41</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dattwyler 1987<a class="bibr" href="#ch5.ref42" rid="ch5.ref42"><sup>42</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dattwyler 1988<a class="bibr" href="#ch5.ref43" rid="ch5.ref43"><sup>43</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dattwyler 2005<a class="bibr" href="#ch5.ref44" rid="ch5.ref44"><sup>44</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dersch 2015<a class="bibr" href="#ch5.ref46" rid="ch5.ref46"><sup>46</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dersch 2016<a class="bibr" href="#ch5.ref49" rid="ch5.ref49"><sup>49</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dersch 2014<a class="bibr" href="#ch5.ref47" rid="ch5.ref47"><sup>47</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dersch 2017<a class="bibr" href="#ch5.ref48" rid="ch5.ref48"><sup>48</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not available</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dhoot 2011<a class="bibr" href="#ch5.ref50" rid="ch5.ref50"><sup>50</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dinser 2005<a class="bibr" href="#ch5.ref51" rid="ch5.ref51"><sup>51</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dotevall 1988<a class="bibr" href="#ch5.ref52" rid="ch5.ref52"><sup>52</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eliassen 2017<a class="bibr" href="#ch5.ref53" rid="ch5.ref53"><sup>53</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eliassen 2017<a class="bibr" href="#ch5.ref54" rid="ch5.ref54"><sup>54</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eppes 2003<a class="bibr" href="#ch5.ref55" rid="ch5.ref55"><sup>55</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Esposito 2013<a class="bibr" href="#ch5.ref56" rid="ch5.ref56"><sup>56</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fallon 1999<a class="bibr" href="#ch5.ref58" rid="ch5.ref58"><sup>58</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Galev 2005<a class="bibr" href="#ch5.ref59" rid="ch5.ref59"><sup>59</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Garkowski 2017<a class="bibr" href="#ch5.ref60" rid="ch5.ref60"><sup>60</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Systematic review</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gasser 1996<a class="bibr" href="#ch5.ref62" rid="ch5.ref62"><sup>62</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not available</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gasser 1995<a class="bibr" href="#ch5.ref63" rid="ch5.ref63"><sup>63</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gasser 1995<a class="bibr" href="#ch5.ref61" rid="ch5.ref61"><sup>61</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gerber 1996<a class="bibr" href="#ch5.ref64" rid="ch5.ref64"><sup>64</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gillies 2015<a class="bibr" href="#ch5.ref65" rid="ch5.ref65"><sup>65</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Goodwin 1990<a class="bibr" href="#ch5.ref66" rid="ch5.ref66"><sup>66</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hansen 1992<a class="bibr" href="#ch5.ref67" rid="ch5.ref67"><sup>67</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hassler 1990<a class="bibr" href="#ch5.ref68" rid="ch5.ref68"><sup>68</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Horton 2017<a class="bibr" href="#ch5.ref69" rid="ch5.ref69"><sup>69</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Conference
|
|
abstract</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hu 2001<a class="bibr" href="#ch5.ref70" rid="ch5.ref70"><sup>70</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inboriboon 2010<a class="bibr" href="#ch5.ref71" rid="ch5.ref71"><sup>71</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Karkkonen 2001<a class="bibr" href="#ch5.ref73" rid="ch5.ref73"><sup>73</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Karlsson 1996<a class="bibr" href="#ch5.ref74" rid="ch5.ref74"><sup>74</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Kersten 1995<a class="bibr" href="#ch5.ref75" rid="ch5.ref75"><sup>75</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Kilic Muftuoglu
|
|
2016<a class="bibr" href="#ch5.ref76" rid="ch5.ref76"><sup>76</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Klempner 2013<a class="bibr" href="#ch5.ref78" rid="ch5.ref78"><sup>78</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Korenberg 1996<a class="bibr" href="#ch5.ref79" rid="ch5.ref79"><sup>79</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Kowalski 2010<a class="bibr" href="#ch5.ref81" rid="ch5.ref81"><sup>81</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Kowalski 2011<a class="bibr" href="#ch5.ref80" rid="ch5.ref80"><sup>80</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Krbkova 1996<a class="bibr" href="#ch5.ref82" rid="ch5.ref82"><sup>82</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Kuhn 2012<a class="bibr" href="#ch5.ref83" rid="ch5.ref83"><sup>83</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Laasila 2003<a class="bibr" href="#ch5.ref84" rid="ch5.ref84"><sup>84</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lantos 2013<a class="bibr" href="#ch5.ref85" rid="ch5.ref85"><sup>85</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lauhio 1994<a class="bibr" href="#ch5.ref86" rid="ch5.ref86"><sup>86</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lauhio 1991<a class="bibr" href="#ch5.ref87" rid="ch5.ref87"><sup>87</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lempner 2002<a class="bibr" href="#ch5.ref77" rid="ch5.ref77"><sup>77</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liegner 1992<a class="bibr" href="#ch5.ref88" rid="ch5.ref88"><sup>88</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lipsker 2002<a class="bibr" href="#ch5.ref89" rid="ch5.ref89"><sup>89</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ljostad 2008<a class="bibr" href="#ch5.ref90" rid="ch5.ref90"><sup>90</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Study abstract</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Loewen 1999<a class="bibr" href="#ch5.ref91" rid="ch5.ref91"><sup>91</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Loewen 2000<a class="bibr" href="#ch5.ref92" rid="ch5.ref92"><sup>92</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Luft 1988<a class="bibr" href="#ch5.ref94" rid="ch5.ref94"><sup>94</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Luft 1989<a class="bibr" href="#ch5.ref93" rid="ch5.ref93"><sup>93</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Maraspin 1995<a class="bibr" href="#ch5.ref100" rid="ch5.ref100"><sup>100</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Maraspin 1996<a class="bibr" href="#ch5.ref95" rid="ch5.ref95"><sup>95</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Maraspin 1999<a class="bibr" href="#ch5.ref96" rid="ch5.ref96"><sup>96</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Maraspin 2002<a class="bibr" href="#ch5.ref97" rid="ch5.ref97"><sup>97</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Maraspin 1999<a class="bibr" href="#ch5.ref98" rid="ch5.ref98"><sup>98</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Maraspin 2002<a class="bibr" href="#ch5.ref99" rid="ch5.ref99"><sup>99</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Marks 2016<a class="bibr" href="#ch5.ref101" rid="ch5.ref101"><sup>101</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">McGill 1965<a class="bibr" href="#ch5.ref102" rid="ch5.ref102"><sup>102</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Meyerhoff 2002<a class="bibr" href="#ch5.ref103" rid="ch5.ref103"><sup>103</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Meyerhoff 2016<a class="bibr" href="#ch5.ref104" rid="ch5.ref104"><sup>104</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Millner 1996<a class="bibr" href="#ch5.ref105" rid="ch5.ref105"><sup>105</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Millner 1996<a class="bibr" href="#ch5.ref106" rid="ch5.ref106"><sup>106</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Morales 2000<a class="bibr" href="#ch5.ref107" rid="ch5.ref107"><sup>107</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muellegger 1995<a class="bibr" href="#ch5.ref109" rid="ch5.ref109"><sup>109</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muellegger 1996<a class="bibr" href="#ch5.ref108" rid="ch5.ref108"><sup>108</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mullegger 1991<a class="bibr" href="#ch5.ref110" rid="ch5.ref110"><sup>110</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nadelman 1993<a class="bibr" href="#ch5.ref112" rid="ch5.ref112"><sup>112</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nadelman 2001<a class="bibr" href="#ch5.ref111" rid="ch5.ref111"><sup>111</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Naglo 1989<a class="bibr" href="#ch5.ref113" rid="ch5.ref113"><sup>113</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neumann 1987<a class="bibr" href="#ch5.ref116" rid="ch5.ref116"><sup>116</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nimmrich 2014<a class="bibr" href="#ch5.ref118" rid="ch5.ref118"><sup>118</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nowakowski 2000<a class="bibr" href="#ch5.ref119" rid="ch5.ref119"><sup>119</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nowakowski 1995<a class="bibr" href="#ch5.ref120" rid="ch5.ref120"><sup>120</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ogrinc 2006<a class="bibr" href="#ch5.ref121" rid="ch5.ref121"><sup>121</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Oksi 1999<a class="bibr" href="#ch5.ref122" rid="ch5.ref122"><sup>122</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Oksi 2007<a class="bibr" href="#ch5.ref123" rid="ch5.ref123"><sup>123</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Oksi 1998<a class="bibr" href="#ch5.ref124" rid="ch5.ref124"><sup>124</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Peltomaa 1998<a class="bibr" href="#ch5.ref125" rid="ch5.ref125"><sup>125</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pena 1999<a class="bibr" href="#ch5.ref126" rid="ch5.ref126"><sup>126</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Perronne 2015<a class="bibr" href="#ch5.ref127" rid="ch5.ref127"><sup>127</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not available</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pfister 1988<a class="bibr" href="#ch5.ref128" rid="ch5.ref128"><sup>128</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pirila 1951<a class="bibr" href="#ch5.ref131" rid="ch5.ref131"><sup>131</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plorer 1993<a class="bibr" href="#ch5.ref132" rid="ch5.ref132"><sup>132</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plotkin 1991<a class="bibr" href="#ch5.ref133" rid="ch5.ref133"><sup>133</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Puchalska 1996<a class="bibr" href="#ch5.ref134" rid="ch5.ref134"><sup>134</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Puri 2015<a class="bibr" href="#ch5.ref135" rid="ch5.ref135"><sup>135</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Puri 2015<a class="bibr" href="#ch5.ref136" rid="ch5.ref136"><sup>136</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rebman 2015<a class="bibr" href="#ch5.ref137" rid="ch5.ref137"><sup>137</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Renaud 2004<a class="bibr" href="#ch5.ref138" rid="ch5.ref138"><sup>138</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rohacova 1996<a class="bibr" href="#ch5.ref139" rid="ch5.ref139"><sup>139</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rose 1994<a class="bibr" href="#ch5.ref140" rid="ch5.ref140"><sup>140</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rose 1996<a class="bibr" href="#ch5.ref141" rid="ch5.ref141"><sup>141</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rubin 1992<a class="bibr" href="#ch5.ref142" rid="ch5.ref142"><sup>142</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Salazar 2005<a class="bibr" href="#ch5.ref143" rid="ch5.ref143"><sup>143</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Salazar 1993<a class="bibr" href="#ch5.ref144" rid="ch5.ref144"><sup>144</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sanchez 2016<a class="bibr" href="#ch5.ref145" rid="ch5.ref145"><sup>145</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sandstrom 1989<a class="bibr" href="#ch5.ref146" rid="ch5.ref146"><sup>146</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Schmidt 1995<a class="bibr" href="#ch5.ref147" rid="ch5.ref147"><sup>147</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Selby 2008<a class="bibr" href="#ch5.ref148" rid="ch5.ref148"><sup>148</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Shadick 1994<a class="bibr" href="#ch5.ref149" rid="ch5.ref149"><sup>149</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Shadick 1999<a class="bibr" href="#ch5.ref150" rid="ch5.ref150"><sup>150</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Shemenski 2016<a class="bibr" href="#ch5.ref151" rid="ch5.ref151"><sup>151</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Shoemaker 2006<a class="bibr" href="#ch5.ref152" rid="ch5.ref152"><sup>152</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sjowall 2012<a class="bibr" href="#ch5.ref154" rid="ch5.ref154"><sup>154</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sjowall 2011<a class="bibr" href="#ch5.ref153" rid="ch5.ref153"><sup>153</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skogman 2003<a class="bibr" href="#ch5.ref156" rid="ch5.ref156"><sup>156</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skogman 2008<a class="bibr" href="#ch5.ref155" rid="ch5.ref155"><sup>155</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skoldenberg 1988<a class="bibr" href="#ch5.ref157" rid="ch5.ref157"><sup>157</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Smith 2002<a class="bibr" href="#ch5.ref158" rid="ch5.ref158"><sup>158</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Solomon 1998<a class="bibr" href="#ch5.ref159" rid="ch5.ref159"><sup>159</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spathling 1992<a class="bibr" href="#ch5.ref160" rid="ch5.ref160"><sup>160</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Article not in
|
|
English</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stanek 1999<a class="bibr" href="#ch5.ref161" rid="ch5.ref161"><sup>161</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Steere 1980<a class="bibr" href="#ch5.ref165" rid="ch5.ref165"><sup>165</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Steere 1983<a class="bibr" href="#ch5.ref166" rid="ch5.ref166"><sup>166</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Steere 1987<a class="bibr" href="#ch5.ref162" rid="ch5.ref162"><sup>162</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Steurer 2016<a class="bibr" href="#ch5.ref167" rid="ch5.ref167"><sup>167</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Article not in
|
|
English</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stricker 2011<a class="bibr" href="#ch5.ref168" rid="ch5.ref168"><sup>168</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stricker 2010<a class="bibr" href="#ch5.ref169" rid="ch5.ref169"><sup>169</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Strle 1996<a class="bibr" href="#ch5.ref170" rid="ch5.ref170"><sup>170</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Strle 1996<a class="bibr" href="#ch5.ref171" rid="ch5.ref171"><sup>171</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Strle 1992<a class="bibr" href="#ch5.ref172" rid="ch5.ref172"><sup>172</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Strle 1993<a class="bibr" href="#ch5.ref173" rid="ch5.ref173"><sup>173</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stupica 2015<a class="bibr" href="#ch5.ref175" rid="ch5.ref175"><sup>175</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stupica 2011<a class="bibr" href="#ch5.ref174" rid="ch5.ref174"><sup>174</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Suarez-Magdalena
|
|
2017<a class="bibr" href="#ch5.ref176" rid="ch5.ref176"><sup>176</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not available</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thompson 2012<a class="bibr" href="#ch5.ref177" rid="ch5.ref177"><sup>177</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thorstrand 2002<a class="bibr" href="#ch5.ref178" rid="ch5.ref178"><sup>178</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thyresson 1949<a class="bibr" href="#ch5.ref179" rid="ch5.ref179"><sup>179</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Torbahn 2016<a class="bibr" href="#ch5.ref180" rid="ch5.ref180"><sup>180</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tory 2010<a class="bibr" href="#ch5.ref181" rid="ch5.ref181"><sup>181</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tseng 2017<a class="bibr" href="#ch5.ref182" rid="ch5.ref182"><sup>182</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect outcome</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Valesova 1996<a class="bibr" href="#ch5.ref183" rid="ch5.ref183"><sup>183</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect comparison</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vazquez 2003<a class="bibr" href="#ch5.ref185" rid="ch5.ref185"><sup>185</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vazquez-Lopez 2016<a class="bibr" href="#ch5.ref184" rid="ch5.ref184"><sup>184</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Wahlberg 1994<a class="bibr" href="#ch5.ref186" rid="ch5.ref186"><sup>186</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Weber 1988<a class="bibr" href="#ch5.ref188" rid="ch5.ref188"><sup>188</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Weber 1987<a class="bibr" href="#ch5.ref187" rid="ch5.ref187"><sup>187</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect population</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Weissenbacher 2005<a class="bibr" href="#ch5.ref189" rid="ch5.ref189"><sup>189</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect intervention</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">White 2013<a class="bibr" href="#ch5.ref190" rid="ch5.ref190"><sup>190</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr><tr><td headers="hd_h_ch5.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Zochling 1996<a class="bibr" href="#ch5.ref191" rid="ch5.ref191"><sup>191</sup></a></td><td headers="hd_h_ch5.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excluded due to an
|
|
incorrect study design</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch5appitab2"><div id="ch5.appi.tab2" class="table"><h3><span class="label">Table 9</span><span class="title">Studies excluded from the health economic review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578166/table/ch5.appi.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch5.appi.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch5.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th><th id="hd_h_ch5.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reason for
|
|
exclusion</th></tr></thead><tbody><tr><td headers="hd_h_ch5.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_ch5.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|